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Abbreviations 
 
Ab  Antibody 
ABCC2 ATP binding cassette subfamily C member 2 
AcMPAG Mycophenolic acid acyl glucuronide 
adRP  Autosomal dominant retinitis pigmentosa 
ALAS1 Aminolevulinate delta-synthase 1 
AMP  Adenosine 5’-monophosphate 
AP2  Activating enhancer-binding protein 2 
APC  Antigen-presenting cell 
ATF-2  Cyclic AMP-dependent transcription factor 
ATP  Adenosine 5’-triphosphate 
AUC  Area under the variable versus time curve  
AZA  Azathioprine 
B2M  Beta-2-microglobulin 
BH4  Tetrahydrobiopterin 
bp  Base pair 
C0  Predose concentration 
C2  Concentration 2 hours postdose 
CBS  Cystathionine β-synthase 
CD  Cluster of differentiation 
CDK  Cyclin dependent kinase 
cGMP  Cyclic guanosine 5’-monophosphate 
CKI  CDK inhibitor 
Cmax  Maximum concentration 
Cmin  Minimum concentration 
c-Myc  Myc proto-oncogene protein 
CNI  Calcineurin inhibitor 
Cp  Crossing point 
CREB  cyclic AMP response element-binding protein 
CsA  Cyclosporine A 
CTLA-4 Cytotoxic T lymphocyte antigen 4 
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CV  Coefficient of variation 
CYP  Cytochrome P450 
dGN  Deoxyguanine nucleotide 
E  PCR efficiency 
EC-MPS Enteric coated mycophenolate sodium 
Egr-1  Early growth response protein 1 
EHC  Enterohepatic circulation 
ELP  Elongation complex protein 
FKBP12 FK506 binding protein 12 
GDP  Guanosine 5’-diphosphate 
GI  Gastrointestinal 
GMP  Guanosine 5’-monophosphate 
GN  Guanine nucleotide 
G6PD  Glucose-6-phosphate dehydrogenase 
GTP  Guanosine 5’-triphosphate 
HPRT  Hypoxanthine-guanine phosphoribosyltransferase 
IL-2  Interleukin-2 
IL-2R  Interleukin-2 receptor  
IMP  Inosine 5’-monophosphate 
IMPDH Inosine 5’-monophosphate dehydrogenase 
iNOS  Inducible form of nitric oxide synthase 
IRF-1  Interferon regulatory factor 1 
kb  Kilobase 
LC  Liquid chromatography 
mAb  Monoclonal antibody 
MAPK  Mitogen activated protein kinase 
MHC  Major histocompatibility complex 
MMF  Mycophenolate mofetil 
MPA  Mycophenolic acid 
MPAG  Mycophenolic acid 7-O-glucuronide 
MPAGIs Mycophenolic acid 7-O-glucoside 
MRP2  Multidrug resistance-related protein 2 (encoded by ABCC2)  
mTOR  Mammalian target of rapamycin 
NAD  Nicotinamide adenine dinucleotide (oxidized, NAD+; reduced, NADH) 
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NFAT  Nuclear factor of activated T cells 
NF-κB  Nuclear factor κB 
Nm23  Nucleoside diphosphate kinase 
NO  Nitric oxide 
nt  Nucleotide 
OATP  Organic anion transporting polypeptide 
PBMC  Peripheral blood mononuclear cell 
PCR  Polymerase chain reaction 
PD  Pharmacodynamic 
PK  Pharmacokinetic 
pRb  Retinoblastoma protein 
PRPP  5-phosphoribosyl-1-pyrophosphate 
RGI  Reference gene index 
RIN  RNA integrity number 
RPL 13A Ribosomal protein L13a 
RT  Reverse transcription 
SNP  Single nucleotide polymorphism 
Sp1  Transcription factor Sp1 
TCR  T cell receptor 
TDM  Therapeutic drug monitoring 
tmax  Time to Cmax within dose interval 
UDP  Uridine diphosphate 
UGT  UDP-glucuronosyltransferase or UDP-glucosyltransferase 
UTR  Untranslated region 
XMP  Xanthosine 5’-monophosphate 
 
 
 
Abbreviations are given in italicized upper case letters when representing gene 
symbols.  
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Errata 
 
Page 60, second paragraph: “The IMPDH activity was determined in lysates of CD4+ 
cells and whole blood as described in Paper II” has been corrected to “The IMPDH 
activity was determined in lysates of CD4+ cells as described in Paper II”. 
 
Paper IV: 
Page 16, third paragraph: “for CD4+ and CD8+ cells (n=8)” has been corrected to 
“for CD4+ and CD8+ cells (n=6)”. 
Page 30, Table 1: “DD, diseased donor “has been corrected to: “DD, deceased 
donor.” 
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1. Introduction 
1.1 Immunosuppressive Therapy in Transplantation 
Following solid organ transplantation, most patients require lifelong 
immunosuppressive therapy to prevent allograft rejection. The emergence of novel 
and more effective immunosuppressive agents has dramatically reduced the incidence 
of acute rejection. However, long-term outcomes are still challenged by the adverse 
effects of immunosuppressants, contributing to late graft failure, cardiovascular 
morbidity, opportunistic infections and malignancies. Therefore, optimization of 
immunosuppressive regimens is needed. 
 
Allograft rejection is primarily mediated by activated T cells. Full activation and 
proliferation of naïve T cells in response to alloantigens require three separate but 
complementary signals (Figure 1). The interaction between the T cell receptor 
(TCR)-CD3 complex and a peptide-MHC II (major histocompatibility complex class 
II) expressed on antigen-presenting cells (APCs) provides the first signal (Signal 1). 
The second costimulatory signal is delivered through the binding of T cell surface 
receptors (CD28, CD154) to their respective ligands on the APC (CD80/86, CD40) 
(Signal 2). Together, these two signals promote T cell activation and induce 
expression and secretion of interleukin-2 (IL-2) and the expression of high-affinity 
IL-2 receptors. Binding of IL-2 to the IL-2 receptor initiates the third autocrine 
growth signal required for T cell proliferation (Signal 3). Most immunosuppressants 
target one or more of these signals (Figure 1). By using combination regimens of 
drugs that act on different stages of T cell activation, the dosing and toxicity of each 
agent can be minimized without compromising the total immunosuppressive effect.  
 
With the introduction of cyclosporine (CsA) in the early 1980s, posttransplant 
outcomes improved significantly, and calcineurin inhibitors (CNIs) still provide the 
foundation for most immunosuppressive regimens. The use of tacrolimus has 
increased gradually, and is now the dominant CNI in clinical transplantation (Figure 
2).1 CsA and tacrolimus bind to immunophilins (cyclophilin and FKBP12, 
respectively), forming complexes that inhibit the phosphatase calcineurin.2,3  This 
suppresses the production of NFAT regulated genes like IL-2, thereby inhibiting the 
Introduction – Immunosuppressive Therapy in Transplantation 
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first signal of T cell activation.4 Tacrolimus displays a greater molar potency than 
CsA, but current dosing strategies result in similar immunosuppressive efficacy.5 Both 
agents display considerable nephrotoxicity and a risk of hemolytic-uremic 
syndrome.6,7 Other non-immune effects differ between the CNIs. CsA is associated 
with significantly more hirsuitism, hypertension and hyperlipidemia, while diabetes 
mellitus is reported to be more frequent with tacrolimus.8,9 
 
Antimetabolites like azathioprine (AZA) and mycophenolic acid (MPA) inhibit cell 
proliferation through interference with DNA and RNA synthesis. Since its 
introduction in the mid 1990s, MPA has largely replaced AZA, and is now included in 
most immunosuppressive regimens after transplantation (Figure 2).10-12 MPA inhibitis 
inosine 5’-monophosphate dehydrogenase (IMPDH) and affects mainly activated 
lymphocytes. This offers increased selectivity and decreased toxicity compared to 
AZA. The major non-immune effects of MPA are gastrointestinal (GI) and 
hematological, which generally respond to dose reductions.10-13 
 
Sirolimus and everolimus bind to the immunophilin FKBP12, yielding complexes that 
inhibit the mammalian target of rapamycin (mTOR). This blocks cell proliferation 
induced by growth factors and cytokines (Signal 3).14 The principal adverse effects 
include hyperlipidemia, anemia, thrombocytopenia and impaired wound healing.15,16 
Compared to CNI based regimens, mTOR inhibitors display lower efficacy against 
acute rejections,17 and are thus not regarded as first-line therapy in organ 
transplantation. Still, sirolimus and everolimus constitute valuable therapeutic 
options, e.g. for patients that cannot tolerate CNIs. Furthermore, as mTOR inhibitors 
are associated with antineoplastic effects, their use may be of benefit in patients with 
a high risk of posttransplant malignancies.18  
 
Corticosteroids are used for induction and maintenance therapy, as well as for reversal 
of established allograft rejection. They alter the gene expression of a wide range of 
genes and exert multiple anti-inflammatory and immunomodulatory effects.19 The 
major immunosuppressive effects include suppressed cytokine production, increased 
apoptosis of lymphocytes, altered macrophage migration and inhibition of dendritic 
cells. Owing to their multifarious effects on gene expression and cellular metabolism,  
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Figure 1. Major targets of immunosuppressive agents in T cell activation.  
Activation and proliferation of naïve T cells require three independent signals. Signal 1: 
Interaction of the T cell receptor (TCR) and a peptide-MHC class II (major histocompatibility 
complex) expressed on antigen-presenting cells (APCs) transmits an antigen specific signal. 
Signal 2: Binding of T cell surface receptors (e.g. CD28) to their respective ligands on the 
APC (e.g. CD80/86) provides costimulation. Signal 3: Autocrine stimulation by interleukin-2 
(IL-2) provides proliferative signals involving mammalian target of rapamycin (mTOR) and 
cyclin/cyclin-dependent kinases (CDKs). Examples of immunosuppressive agents that target 
one or more of these signals are shown in white boxes.  
 
AZA, azathioprine; CsA, cyclosporine; IL-2R, interleukine-2 receptor; mAb, monoclonal 
antibody; MAPK, mitogen-activated protein kinase; MPA, mycophenolic acid; NFAT, nuclear 
factor of activated T cells; NF-κB, nuclear factor-κB; TCR, T cell receptor; TF, transcription 
factor 
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corticosteroid treatment is associated with a myriad of side effects that increase the 
risk of cardiovascular disease and metabolic disturbances.19 
 
Induction therapy with antibody (Ab) preparations has increased substantially during 
the last decades. Depleting agents like polyclonal antithymocyte globulin and 
muromonab-CD3 (mouse monoclonal Ab (mAb) against CD3) act by binding to 
lymphocyte cell surface receptors resulting in phagocytosis, cell lysis, apoptosis or 
downregulation of cell surface antigens. This leads to effective immunosuppression 
through long-lasting lymphocyte depletion. Adverse effects include cytokine-release 
syndrome, anaphylactic reactions, thrombocytopenia and an increased risk of 
infections and maglignancies. More recently, non-depleting mAbs against the α-chain 
(CD25) of IL-2 receptor (IL-2R) were introduced and are available as daclizumab 
(humanized) and basiliximab (chimeric). These agents target only activated T cells 
while resting T cells are spared. Compared to the depleting agents, IL-2R mAbs 
demonstrate minimal toxic effects but might be less effective.20,21  
  
At Rikshospitalet University Hospital in Oslo, the current standard 
immunosuppressive regimen after renal transplantation consists of a low-dosed CNI, 
mycophenolate, glucocorticoids and induction therapy (anti-IL-2R mAb). 
 
The successful reduction in acute rejection episodes has shifted the focus towards 
minimizing drug toxicities to improve the long-term outcomes. Current 
immunosuppressive agents are usually characterized by narrow therapeutic indexes 
and broad pharmacokinetic and pharmacodynamic variability. Strategies for improved 
outcomes involve individualized therapy, considering both type of regimen and 
dosing to address the unique immune versus toxic responses of a particular patient. 
Therapeutic drug monitoring (TDM) is a valuable tool for individualization of therapy 
and is routinely used to guide dosing of CNIs and mTOR inhibitors. However, the 
strategy for potential monitoring of MPA is still debated (Section 1.4).22 Further 
efforts focus on protocols that taper or withdraw corticosteroids or CNIs. MPA seems 
to be devoid of nephrotoxic and metabolic side effects and displays potential 
beneficial effects on long-term outcomes, and is therefore frequently used to facilitate 
drug sparing regimens.23 However, the results of drug sparing regimens are so far 
conflicting, and careful selection of patients and monitoring is required. Moreover, 
Introduction – Immunosuppressive Therapy in Transplantation 
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development of novel, potent agents with increased specificity against alloimmune 
responses could improve long-term outcomes. A T cell costimulation blocker, 
belatacept, is currently undergoing phase III clinical trials in renal transplantation. 
Belatacept is a second generation CTLA-4 IgG fusion protein, which binds to CD80 
and CD86 on APCs and thereby inhibits the costimulatory signal through CD28 on T 
cells (Figure 1).24 Data from a phase II trial demonstrated similar efficacy and less 
adverse effects compared to CsA,25 implying that belatacept might be a promising 
alternative to CsA or corticosteroids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Immunosuppressive agents in renal transplantation. 
Clinical use of maintenance immunosuppression in renal transplant patients prior to discharge 
from 1995 to 2005 (Based on US data from the 2006 OPTN/SRTR Annual Report) 
 
AZA, azathioprine; CsA, cyclosporine; MPA, mycophenolic acid 
 
 
The use of MPA is steadily growing in transplantation (Figure 2),1 as well as for 
several autoimmune diseases. However, the utilization of this drug is hampered by GI 
and hematological toxicities and an increased risk of opportunistic infections,10-13 
which requires frequent dose reductions or withdrawal.26,27 Consequently, there is an 
increasing focus on individualization of MPA therapy to improve the tolerability and 
thereby enhance the therapeutic potential of this agent.  
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The establishment of feasible strategies for individualization of MPA therapy requires 
substantial insight into MPA pharmacokinetics and pharmacodynamics. This includes 
investigations of the relation between MPA, the molecular target IMPDH, and finally 
the clinical outcome. Further knowledge of IMPDH and its regulation is also 
important within fields like antiviral and anticancer therapy, as well as in 
development of novel IMPDH inhibitors. 
Introduction – Inosine Monophosphate Dehydrogenase 
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1.2 Inosine Monophosphate Dehydrogenase 
1.2.1 Biosynthetic pathways 
Adequate levels of purine nucleotides are essential for cell proliferation, cell signaling 
and as a biochemical energy source. Because the intracellular pools of nucleotides 
(except ATP) are relatively small, continuous generation of nucleotides is required. 
Purine nucleotide levels are maintained through a combination of de novo and salvage 
biosynthesis pathways (Figure 3). Both pathways utilize the activated sugar 
5-phosphoribosyl-1-pyrophosphate (PRPP), which is generated from ribose 
5’-phosphate and ATP. The de novo pathway converts PRPP through ten biosynthetic 
steps into inosine 5’-monophosphate (IMP). This represents a branch point in the 
purine nucleotide synthesis and IMP is further converted to either guanine or adenine 
nucleotides. Inosine 5’-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205) 
catalyzes the conversion of IMP to xanthosine 5’-monophosphate (XMP), which is 
the rate-limiting step in de novo synthesis of guanine and deoxyguanine nucleotides 
(Figure 3).28 GMP synthetase converts XMP to guanosine 5’-monophosphate (GMP), 
which is further phosphorylated to guanosine di- (GDP) and triphosphates (GTP). 
Furthermore, ribonucleotide reductase converts GDP to deoxy GDP (dGDP), which is 
subsequently phosphorylated to dGTP.  
 
Salvage pathways recycle free purine bases and nucleosides, originating from nucleic 
acid breakdown or cellular uptake, into their corresponding nucleotides (Figure 3). 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) is a principal enzyme in 
the salvage of guanine and hypoxanthine into GMP and IMP, respectively. PRPP 
serves as a ribose phosphate donor. Dependence on de novo and salvage pathways is 
largely cell type and cell cycle specific. Salvage pathways seem to be the predominant 
source of purine nucleotides in most cell types. In contrast, lymphocytes are critically 
dependent on de novo purine synthesis for initiation of proliferative responses. The 
relative contributions of de novo and salvage pathways remain to be definitively 
elucidated in various cell populations and conditions.  
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Figure 3. Schematic overview of purine nucleotide biosynthesis.  
The main steps of de novo (continuous arrows) and salvage pathways (dashed arrows) of 
adenine nucleotide (grey) and (deoxy) guanine nucleotide synthesis (black). Both pathways 
utilize 5-phosphoribosyl-1-pyrophosphate (PRPP), which is synthesized by PRPP synthetase. 
Inosine 5’-monophosphate dehydrogenase (IMPDH) and hypoxanthine guanine 
phosphoribosyltransferase (HPRT) are pivotal enzymes in de novo and salvage GMP 
synthesis, respectively.  
 
A, adenine; AMP, adenosine 5’-monophophate; AR, adenosine; dGDP, deoxyguanosine 
diphosphate; dGTP, deoxyguanosine triphosphate; G, guanine; GMP, guanosine 5’-
monophosphate; GDP, guanosine 5’-diphosphate; GR, guanosine; GTP, guanosine 5’-
triphosphate; Hx, hypoxanthine; HxR, inosine; IMP, inosine 5’-monophosphate; XMP, 
xanthosine 5’-monophosphate 
 
 
de novo
pathway
DNA
Ribose-5-phosphate + ATP RNA
PRPP 
synthetase
Salvage
pathway
dGDPGDP
dGTPPRPP GTP
IMPDH
RNA   DNA
A G
HPRT
IMP
HxR GRAR
XMP GMPAMP
Hx
A GHx
PRPP
Introduction – Inosine Monophosphate Dehydrogenase 
 19 
The biosynthesis of purine nucleotides is tightly controlled through feedback 
regulation of rate-limiting enzymes. The control mechanisms are widely studied in  
prokaryotes and lower eukaryotes (e.g. yeast),29-32 but are less characterized in 
mammals. In human lymphocytes, PRPP synthetase is reported to be under allosteric 
control by adenine and guanine nucleotides, leading to suppressed and increased 
activity, respectively.33 The activity of ribonucleotide reductase is reported to be 
reduced by excess levels of dATP, while dGTP binding stimulated the enzyme.33 
Furthermore, IMPDH is suggested to be subject to both enzymatic and transcriptional 
feedback control. E.coli enzyme models have demonstrated allosteric or competitive 
feedback regulation of IMPDH activity by GMP.29,30 However, the contributions of 
these mechanisms in vivo in human cells are poorly defined. On the other hand, 
studies in human cells have reported feedback regulation at the transcriptional level 
(Sections 1.2.2 and 1.4.4).34,35 Pimkin et al. speculated that regulation at the 
enzymatic level might be the first-line control while transcriptional regulation is a 
slower and secondary control mechanism.30 
 
As GMP constitutes the smallest of purine and pyrimidine ribonucleotide pools, the 
guanine nucleotide levels are particularly sensitive to biosynthetic modulation.36 
Production of dGTP and GTP is required for DNA and RNA synthesis, respectively. 
Guanine nucleotides are further essential for cellular signaling and trafficking. 
Moreover, the activity of IMPDH has been reported to be a critical determinant of 
p53-dependent growth control.37 This implies that IMPDH plays an important role in 
the regulation of cell proliferation, differentiation and death.  
 
1.2.2 Genes and regulation 
Genes encoding IMPDH are found in all eukaryotes and most prokaryotes, and are 
highly conserved across species.38 Human IMPDH activity is constituted by two 
isoenzymes, IMPDH type 1 and type 2, which are encoded by IMPDH1 and 
IMPDH2, respectively. The genes are located on chromosomes 7q31.3-q32 and 
3p21.2-p24.2 and demonstrate similar coding exon structures with highly conserved 
exon-intron boundaries36,39,40 and approximately 76% nucleotide sequence identity in 
coding regions.41 The IMPDH2 gene is 5.8 kb in length with 14 exons (49 to 207 bp) 
and introns ranging from 73 to 1065 bp, while the IMPDH1 gene is considerable 
Introduction – Inosine Monophosphate Dehydrogenase 
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larger (>18 kb) with introns from 88 to longer than 3200 bp.42 Furthermore, the 
IMPDH1 gene includes three additional exons at the 5’ end (A, B, C), a recently 
discovered exon (13b) located between exon 13 and 14 and an extra noncoding region 
of exon 14 at the 3’ end (Figure 4).43 The distinct intron sizes and sequence 
divergence of the genes, suggests that the isoforms have arisen from an early gene 
duplication event, while the conservation of two isoenzymes with similar catalytic 
activity implies separate and essential functions of both proteins. Multiple processed 
pseudogenes have been generated from IMPDH1, whereas none are identified to 
origin from IMPDH2. The IMPDH1P11 pseudogene (previously IMPDH1L) displays 
90% sequence identity to IMPDH1 and 72% identity to IMPDH2.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The genomic structure of IMPDH1 and IMPDH2. 
Organization of the IMPDH1 (A) and IMPDH2 (B) genes. Coding and noncoding 
exons/regions of exons are represented by grey and black boxes, respectively. Black/white 
striped boxes show IMPDH1 exons/regions that are protein coding in retinal cells. Potential 
promoters (P) are illustrated as white rectangles. Genetic variants that have been associated 
with outcomes after transplantation or IMPDH activity (Section 1.4.3) are indicated with 
arrows. The locations and lengths of the target sequences of the quantitative reverse 
transcription-PCR assay (Section 3.1 and Paper I) are indicated.  
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The IMPDH genes are regulated at the transcriptional level, but the detailed 
mechanisms are not known. The 5’ flanking region of IMPDH2 has been reported to 
contain several transcription binding motifs including two cAMP response elements 
(CRE), an Sp1 site, an overlapping Egr-1/Sp1 site, an Nm23 motif and a palindromic 
octamer sequence (POS).45 Because promoter sites have been shown to be occupied in 
unstimulated as well as stimulated cells, the regulation of IMPDH2 appears to involve 
protein-protein interactions or posttranslational modifications of the bound 
transcription factors.45,46 The transcription factors ATF-2 and Sp1, and a POS-binding 
protein are suggested to be involved in T cell regulation.45 
 
The level and pattern of IMPDH1 expression is generally more variable than that of 
IMPDH2.47 This may be attributed to alternative splicing and utilization of at least 
three IMPDH1 promoters (P1, P2 and P3; Figure 4), resulting in the generation of 
various IMPDH1 transcripts.42 Of these, a 4.0 kb transcript is reported to be expressed 
mainly in activated T cells and monocytes, while a 2.5 kb transcript predominates in 
most tissues.42 Another 2.7 kb transcript was primarily found in transformed cells. 
These transcripts differ only in the 5’ untranslated regions (Exons A, B, C), contain 
identical coding sequences from exons 1−14 and encode identical proteins of 514 
amino acids, denoted as canonical IMPDH1.42 More recent findings revealed novel 
IMPDH1 transcripts and proteins in human and mouse retinal cells, probably deriving 
from a combination of alternative splicing, different transcription/translation initiation 
sites and/or inclusion of the 13b exon (17 bp). The predominant retinal variants are 
proteins of 546 (IMPDH1α) and 595 (IMPDH1γ) amino acids.48 Both variants include 
5 alternative and 32 additional amino acids (exon 13b+14) at the C-terminus 
compared to the canonical IMPDH1. The IMPDH1γ variant additionally includes 49 
amino acids (exon A) at the N-terminus resulting from an alternative initiation 
site.43,48 Potential binding sites for Sp1, AP2, Ets-1, PuF, SIF, ELP, Nm23, CREB and 
NF-κB have been identified at the IMPDH1 promoter sequences.36,42,49 
 
The factors regulating expression of the IMPDH genes are poorly characterized. Myc 
proto-oncogene protein (c-Myc) is a key regulator of cell cycle progression and has 
been demonstrated to induce expression of both IMPDH1 and IMPDH2.50,51 In 
contrast, the tumor antigen p53 is reported to downregulate expression of IMPDH2, 
Introduction – Inosine Monophosphate Dehydrogenase 
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IMPDH activity and consequently guanine nucleotide levels, and this is considered a 
critical part of growth regulation in p53-dependent processes.37,52 
 
Studies in yeast (S. cerevisiae) and human blood cells suggest feedback regulation of 
IMPDH gene expressions by guanine nucleotides.31,34,35,53 A model in yeast recently 
proposed GTP-dependent start site selection and transcription attenuation as a 
mechanism for IMPDH regulation.32 In human, in vitro studies in transformed cells 
demonstrated upregulation of IMPDH 1 and 2 expression during exposure to guanine 
nucleotide depleting agents,34,53 whereas addition of salvage precursors increased 
guanine nucleotide levels and reduced gene expression.34 Dayton et al. reported 
similar feedback regulation of IMPDH2 in normal human T cells.35 However, the 
feedback regulation of IMPDH in human cells is debated, the underlying molecular 
mechanisms have not been determined and in vivo data are sparse. In a study of 
healthy individuals exposed to escalating MMF doses, IMPDH1 expression tended to 
be inversely correlated to GTP concentrations (Paper III). The MPA mediated 
changes of IMPDH expression are further discussed in Section 1.4.4 and in the Papers 
II-IV. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Regulation of IMPDH1 and/or IMPDH2 expression. 
Schematic view of factors that may regulate the expression of IMPDH1 and/or IMPDH2 in 
human cells. Arrows indicate stimulation while T-bars represent inhibition. 
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The p53-dependent mechanisms that regulate IMPDH gene expression for growth 
control are suggested to be distinct from the feedback regulation by guanine 
nucleotides. Such a bipartite regulation might be expected for genes which encode 
products that are required both for constitutive anabolic processes (e.g. RNA and 
DNA synthesis) and for conditional molecular regulation (e.g. growth control).54 
 
1.2.3 IMPDH isoenzymes 
Both IMPDH 1 and 2 constitute proteins of 56 kDa with 84% identity at the amino-
acid level.41 Moreover, substrate affinities and catalytic activities are comparable 
between the isoenzymes.55 Despite substantial similarities, IMPDH 1 and 2 are 
differently expressed in various tissues and are subject to distinct mechanisms of 
regulation.56,57 Both isoenzymes are widely expressed, and most cells types display 
higher expression of IMPDH2 than of IMPDH1. The highest levels of IMPDH1 are 
observed in resting and activated peripheral blood lymphocytes.47,57,58 Furthermore, 
variants of IMPDH1  are highly expressed in retinal cells, displaying 10-fold higher 
expression than of IMPDH2 (Section 1.2.2).59 This suggests a critical role of 
IMPDH1 for photoreceptor function.  
Malignant transformation is associated with an upregulation of IMPDH activity and 
the gene expression of IMPDH2 (Section 1.2.6).36,60 Both isoenzymes are involved in 
lymphocyte proliferation. Ex vivo stimulation of normal peripheral T cells induced the 
expression of IMPDH 1 and 2 up to 10 times the levels in resting cells. This was 
accompanied by a 15-fold increase in enzyme activity and 6-fold elevation of GTP 
within 72 hours after activation.35,58 
The relative biological roles of IMPDH1 and IMPDH2 have been investigated in gene 
knockout mouse models. Loss of both IMPDH2 alleles resulted in early embryonic 
lethality, while heterozygous IMPDH2 knockouts displayed no significant phenotype 
changes. However, in combination with homozygous HPRT knockout, heterozygous 
IMPDH2 lymphocytes demonstrated impaired proliferative responses to mitogens and 
decreased cytolytic function.56 In contrast, homozygous IMPDH1 knockout mice 
seemed to have normal development and fertility, and lymphocytes demonstrated 
normal proliferative responses, also with combined HPRT knockout.57 These findings 
suggest that IMPDH2 is essential for normal development and fertility and that the 
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collective actions of IMPDH1, IMPDH2 and HPRT provide the increase in guanine 
nucleotides that is required for lymphocyte activation.56,57 
 
1.2.4 Catalytic cycle 
The two IMPDH isoenzymes display common catalytic mechanisms and 
indistinguishable activities.55  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Catalytic reaction of IMPDH. 
Potential mechanism for the catalytic conversion of inosine 5’-monophosphate (IMP) to 
xanthosine 5’-monophosphate (XMP) by the enzyme IMP dehydrogenase (IMPDH). The 
catalytic loop containing the active site cysteine is shown in black. The mobile flap is shown in 
dark grey and folds into the nicotinamide adenine dinucleotide (NAD) site after NADH is 
released. Mycophenolic acid (MPA) competes with the flap for the NAD site. Binding of MPA 
causes an allosteric conformational change that traps the enzyme-XMP* intermediate.  
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IMPDH catalyzes two distinct chemical transformations, a dehydrogenase reaction 
and a hydrolysis reaction, which are accompanied by a shift between an open and a 
closed conformation (Figure 6). IMPDH binds IMP at its active site and the reaction 
is initialized by a nucleophilic attack of an active site cysteine (Cys 331) on the C2 
position of IMP to form a covalent intermediate (E-IMP). Binding of nicotinamide-
adenine dinucleotide (NAD+) results in hydride transfer, release of NADH and an 
oxidized intermediate covalently bound to IMPDH (thioimidate, E-XMP*). A mobile 
loop structure, called a flap, moves into the vacant NAD site and activates water for 
E-XMP* hydrolysis, and finally free XMP is released.38,61,62 The enzyme requires the 
presence of potassium,63 which is probably involved in stabilization of the NAD 
site.38  
 
1.2.5 Protein structure 
Several crystal structures of IMPDH 1 and 2 from various organisms have provided 
the basis for models of structure-function relations of the isoenzymes. The human 
IMPDH1 and IMPDH2 proteins exist as homotetramers of 56 kDa monomers.64  Each 
monomer consists of two structurally discrete domains, a catalytic core domain and a 
subdomain. The catalytic domain constitutes approximately 400 amino acids in an 
eight-stranded α/β-barrel fold. A cleft in the barrel, close to the interface between two 
monomers, forms an active site. The IMP and NAD+ binding sites are located within 
this cleft and are partly covered by a mobile flap of 50 residues (Figure 7).38,62,65,66  
 
The subdomain, also referred to as a Bateman domain, constitutes about 120 residues 
within the sequence of the catalytic domain and appears to be appended to the protein 
core as an independent folding unit. The Bateman domain includes two tandem 
repeats of a cystathionine β-synthase (CBS) like motif.38,67  
 
Although the Bateman domain is highly evolutionary conserved, no specific functions 
have been established for the subdomain. Amino acid substitutions, as well as 
complete deletion of this structure does not impact catalytic activity in vitro.59,68 The 
subdomain has been reported to bind non-sequence-specific single-stranded nucleic 
acids and to be associated with polyribosomes.68-70 These observations suggest a 
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direct role in gene transcription or translation.68-71 Furthermore, a recent study 
proposed a function in the regulation of adenine nucleotide levels and purine 
nucleotide turnover.72 This implies that the physiological importance of IMPDH may 
extend beyond its primary role in de novo guanine nucleotide biosynthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic illustration of the IMPDH homotetramer structure.  
The catalytic core domains are presented in light grey. The active site contains a catalytic 
loop, shown in black, and a mobile flap illustrated in grey. Binding sites for inosine 
5’-monophosphate (IMP) and nicotinamide adenine dinucleotide (NAD+) are located at the 
monomer interfaces.  
 
1.2.6 IMPDH and pathophysiology 
The activity and expression of IMPDH2 has been reported to be greatly increased in 
solid neoplastic and leukemic cells.60,73 Furthermore, treatment response and 
resistance to cancer chemotherapy has been correlated to IMPDH activity and gene 
expression.74,75 This has made the enzyme an attractive target for development of 
anticancer agents, as well as for monitoring the clinical response to cancer 
therapy.75,76  
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Missense mutations within the IMPDH1 gene cause the RP10 form of autosomal 
dominant retinitis pigmentosa (adRP), accounting for 2−3% of adRP cases, and are 
also a cause of rare cases of Leber congenital amaurosis.59,77 The pathogenic 
mutations are located within or proximate to the CBS coding sequence and do not 
affect enzymatic activity. However, the mutations seem to alter the nucleic acid 
binding and polyribosome association properties of IMPDH1.43,68-70 These 
observations suggest that IMPDH1 has a role in RNA metabolism that is crucial for 
photoreceptor function. The pathophysiology of retinal degeneration may be mediated 
through the presence of unique retinal IMPDH1 isoforms (Section 1.2.2).43 However, 
the detailed mechanism of the retinal degradation remains to be elucidated. The 
association between IMPDH1 polymorphisms and adRP has further increased the 
interest in IMPDH biology. 
 
1.2.7 Inhibitors of IMPDH 
The pivotal role of IMPDH in de novo guanine nucleotide biosynthesis makes this 
enzyme essential in cell proliferation and differentiation, and thus a potential target 
for immunosuppressive, anticancer, antiviral, antiparasitic or antimicrobial effects.78 
Several classes of IMPDH inhibitors are now either in use or under development. On 
a structural basis the inhibitors in current clinical use can be divided into nucleoside 
(ribavirin, mizoribine and tiazofurin) and non-nucleoside inhibitors (MPA). Ribavirin 
and mizoribine undergo intracellular phosphorylation to their respective 
5’-monophosphates, which bind competitively at the IMP site of IMPDH. Ribavirin 
displays broad antiviral activity and is used for the treatment of respiratory syncytial 
virus (RSV) and in combination with interferon-α, for the treatment of chronic 
hepatitis C viral (HCV) infection.79 Mizoribine is widely used in Japan for prevention 
of rejection after renal transplantation, and for treatment of lupus nephritis, 
rheumatoid arthritis and nephritic syndrome.80 Tiazofurin is activated to the NAD 
analog, tiazofurin adenine dinucleotide (TAD), which binds competitively at the NAD 
site of IMPDH. It demonstrates widespread antineoplastic activity and was tested in 
clinical phase I/II trials, but considerable toxicity prevented further clinical testing. 
The agent has been used “off-label” in patients for treatment of blast crisis of chronic 
myelogenous leukemia (CML).81  
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Mycophenolic acid (MPA, Figure 9) is a non-nucleoside agent, which mediates 
uncompetitive and reversible inhibition of human IMPDH type 1 and 2.55,64 MPA 
binds to the NAD site after NADH release and causes an allosteric modification of the 
enzyme that traps the E-XMP* intermediate, preventing release of XMP (Figure 6).65 
MPA is nearly 5 times more potent as inhibitor of IMPDH2 than of IMPDH1, 
displaying inhibition constants (Ki) of 7.0×10-9 and 3.3×10-8 M, respectively.64  
 
None of the IMPDH inhibitors in current use are strictly isoenzyme selective.  
Traditionally, attention has been directed at development of selective IMPDH2 
inhibitors for anticancer and immunosuppressive actions.64 More recently, both 
isoenzymes have been demonstrated to be involved in lymphocyte proliferation and 
thus potential targets for immunosuppressive effects.35,58 Although IMPDH2 is the 
predominant isoenzyme in malignant cells and drug development has been targeted at 
this isoenzyme, expression of IMPDH1 has recently been associated with tumor 
angiogenesis,82 suggesting that both isoenzymes could be potential targets also for 
anticancer therapy.  
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1.3 Mycophenolic Acid 
Mycophenolic acid (MPA) was probably first discovered by Gosio in 1896 and is a 
fermentation product of several Penicillum species. Early investigations demonstrated 
antineoplastic, antifungal, antiviral, anti-inflammatory and immunosuppressive 
activity of this compound. Despite promising antitumor activity in experimental 
models, the susceptibility of MPA to metabolic inactivation rendered it ineffective in 
clinical anticancer therapy.83 It is now widely used as an immunosuppressant in 
transplantation and has been established in therapy of autoimmune disorders like 
lupus nephropathy.84  
1.3.1 Mechanisms of action  
Inhibition of IMPDH by MPA leads to reduced levels of intracellular guanine and 
deoxyguanine nucleotides.85 This induces a range of cellular effects, depending on 
cell type, differentiation and cycle status. The direct relationship between biologic 
activity and guanine nucleotide depletion was established in vitro by the reversibility 
of MPA effects with repletion of the guanine nucleotide pools.85,86 Furthermore, MPA 
has also been reported to affect adenine nucleotide levels.87 Cellular effects of MPA 
are illustrated in Figure 8. 
 
Cell cycle arrest 
The immunosuppressive actions of MPA are primarily related to the inhibition of T 
and B cell proliferation.84 Proliferating lymphocytes and monocytes largely depend on 
de novo guanine nucleotide synthesis because the salvage pathways cannot alone 
provide the required guanine nucleotides in these cells.85 In vitro experiments 
proposed that the suppressed proliferation was related to the depletion of dGTP 
pools.78 Moreover, MPA displays antiproliferative properties in non-immune cells, 
including renal tubular cells, mesangial cells, vascular smooth muscle cells, 
endothelial cells and fibroblasts.88-92 The mechanisms underlying the antiproliferative 
effects have been investigated in many cell models and are reported to involve altered 
expression of cell cycle regulatory proteins, inhibited phosphorylation of 
retinoblastoma protein (pRb) and finally cell cycle arrest in G1 phase.93,94 
Furthermore, inhibition of RNA primed DNA synthesis has been demonstrated in 
leukemic T cell lines.95  
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Progression of cell cycle is controlled by the activity of a series of cyclin-dependent 
kinases (CDKs), which in turn are regulated by the binding of cyclins and the 
expression of CDK inhibitors (CKIs). The cyclin-CDK complexes phosphorylate 
pRb, resulting in the liberation of the transcription factor E2F and subsequently 
activation of genes required for cell proliferation to proceed (Figure 8). The upstream 
mechanisms that sense guanine nucleotide depletion and trigger cell cycle arrest are 
still not clear and seem to differ between cell types. Studies in human cell lines 
(osteosarcoma and normal fibroblasts) demonstrated that MPA resulted in 
p53-dependent G0/G1 cell cycle arrest, mediated through induction of p53 and 
p21Cip1Waf1 (CKI) and subsequent dephosphorylation of pRb.94,96 The MPA induced 
activation of p53 might be caused by suppressed pre-rRNA synthesis, nucleolar stress 
and enhanced interaction of MDM2 with ribosomal proteins L5 and L11.96,97 In 
contrast to this p53-dependent mechanism, stimulated T cells demonstrated an MPA 
induced G1 block that was only associated with a modest increase of p53, whereas 
p21Cip1/Waf1 (CKI) was not altered.93,98 The cell cycle arrest in these cells involved 
inhibited induction of cyclin D3, and to a lesser extent of cyclin D2, CDK6 and 
CDK2 levels, in conjunction with reduced degradation of p27Kip1 (CKI), thereby 
resulting in reduced pRb phosphorylation.93,98 
 
Cell differentiation 
In some cell types, the MPA mediated reduction of GTP levels also influences 
differentiation and maturation. Transformed myeloid and erythroid cell lines and 
leukemic cells from patients were induced to differentiate by MPA,99,100 and this 
emphasizes the potential of IMPDH inhibitors in anticancer therapy. On the other 
hand, MPA has been reported to suppress the maturation and functions of normal 
dendritic and CD8+ cells, which could contribute to the immunomodulative effects of 
this agent.101,102 
 
Cell death 
In addition to the cytostatic effects, MPA also mediates cytotoxic effects depending 
on cell type and activation state. It is reported to induce apoptosis in lymphocyte- and 
macrophage-monocyte lineage cell lines.86 The cytotoxic effects probably occur 
through both caspase-dependent103 and caspase-independent104 processes, but the
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Figure 8. Summary of established and potential cellular effects of 
mycophenolic acid (MPA).  
The effects depend on cell type and proliferation status. Relevant cell types are indicated in 
the white boxes. Arrows represent stimulation while T-bars represent inhibition. 
 
indicates processes that might be suppressed by MPA.   
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detailed mechanisms are still poorly defined. A recent report proposes that the major 
cytotoxic action of MPA in lymphocytes is mediated through activation of a caspase-
independent necrotic signal.105 
 
Glycoprotein synthesis 
MPA also acts at the level of leukocyte recruitment, antigen presentation and 
leukocyte effector functions. Depletion of GTP inhibits the transfer of fucose and 
mannose during synthesis of glycoproteins,78 which include several adhesion and 
costimulatory molecules. This decreases the recruitment of leukocytes into sites of 
inflammation and suppresses both the initiation and the effector phase of immune 
responses.106  
 
Nitric oxide production 
Inducible nitric oxide synthetase (iNOS) catalyzes the conversion of L-arginine to 
NO. The enzyme is involved in several inflammatory pathways and iNOS activation 
is correlated with renal allograft rejection.107 MPA is reported to inhibit iNOS,108 
probably through cell type specific mechanisms. In endothelial cells, reduced GTP 
levels suppressed synthesis of the tetrahydrobiopterin (BH4), which is an essential 
cofactor for enzyme activity.108 In fibroblasts, however, the regulation is probably due 
to impaired activation of the iNOS transcription factor IRF-1.109 
 
Cellular signal transduction 
Other immune modulating effects of MPA include interference with cellular signaling 
pathways that are involved in immunological or pathological processes. Decreased 
availability of GTP has been reported to interfere with the function of guanine 
nucleotide binding proteins (G proteins).78,110,111 This might impair signal pathways 
important for T cell activation and function,111,112 including activation of T cell 
surface antigens.113 Furthermore, alterations of G protein activity has been proposed 
as an underlying molecular and sensing mechanism for the antiproliferative and 
cytotoxic effects of MPA.114,115 Moreover, cyclic GMP (cGMP) is generated from 
GTP and inhibition of IMPDH has been associated with reduced cGMP 
concentrations.116 This might also impact cellular signaling pathways.  
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Aggregate formation 
In addition to the direct inhibition of enzyme activity by MPA, it was reported to 
induce the intracellular formation of IMPDH aggregates, which were observed as 
linear or ring structures.117 The macrostructures were localized in the perinuclear area 
of the cytoplasm and did not seem to be associated with organelles. Addition of GTP 
reversed the aggregate formation117 and the structures appear to be regulated in 
response to changing intracellular GTP levels.48 While both IMPDH 1 and 2 formed 
macrostructures with GTP depletion, the IMPDH2 isoenzyme seemed to be more 
susceptible to aggregation.48 Indeed, the functional impact of this aggregation remains 
to be elucidated.  
 
Clinical effects 
The several mechanisms of actions of MPA provide a wide range of 
immunosuppressive, antiproliferative and anti-inflammatory effects. As well as 
preventing allograft rejection, MPA favours long-term posttransplantation outcomes 
by suppressing proliferation of non-immune cells and reducing inflammation. 
Reported beneficial effects include reduced graft fibrosis, amelioration of CNI 
mediated nephrotoxicity, retarded progression of atherosclerosis and reduced risk of 
malignancies.118-121 Furthermore, the immune modulator function of this drug 
emphasizes the potential of MPA in the treatment of immunologically driven 
inflammatory disorders.  
 
1.3.2 Pharmacokinetics 
MPA is available as the morpholinoethyl ester mycophenolate mofetil (MMF; 
CellCept®) or as enteric-coated mycophenolate sodium (EC-MPS; Myfortic®). The 
drugs are usually administered in fixed doses of 1000 mg MMF or 720 mg EC-MPS 
(~equimolar quantity of MPA) twice daily when used with CsA in adult renal 
transplant patients, while doses of 1500 mg MMF twice daily is recommended when 
administered to cardiac or liver allograft recipients.122,123 MMF has improved oral 
bioavailability, compared to MPA, and is rapidly hydrolyzed by esterases to MPA and 
absorbed in the upper GI, reaching maximum concentration approximately 1−2 hours 
postdose.124 The EC-MPS formulation delays the release of MPA until the drug 
reaches the small intestine.125 The absorption is high from both formulations, resulting 
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in bioavailabilities of approximately 81−95%126,127 and 72% for MMF and EC-MPS, 
respectively.122 Administration of EC-MPS with a high-fat meal was associated with a 
delay in absorption and a reduction of the maximum MPA concentration.122 Thus, it is 
recommended to give EC-MPS on an empty stomach. 
 
MPA displays tight and extensive binding to serum albumin, approximately 97−99% 
in patients with normal renal and liver function.128-131 The binding is reduced by renal 
impairment due to a direct effect of uremia and the accumulation of the 
7-O-glucuronide metabolite of MPA (MPAG), which can displace MPA from 
albumin binding sites.128,132,133 Furthermore, hyperbilirubinemia and 
hypoalbuminemia  might decrease the plasma protein binding of MPA.130,134,135 Only 
the unbound fraction of MPA is pharmacologically active.136  Measurement of the 
free MPA concentration is thus suggested in patients with renal or liver impairment or 
low serum albumin levels (≤31 g/L) to achieve a correct interpretation of unbound 
MPA exposure.134 
 
MPA is metabolized by uridine diphosphate-glucuronosyltransferases (UGTs) 
primarily in the liver, but also in the intestine and kidneys.137,138 The conversion to the 
predominant and pharmacologically inactive MPAG metabolite is catalyzed mainly 
by UGT 1A9, but other UGTs (1A1, 1A6, 1A7, 1A8 and 1A10) are also 
involved.139,140 A minor acyl glucuronide (AcMPAG) metabolite is generated 
primarily by UGT 2B7 and demonstrates pharmacological activity comparable to 
MPA.138,141 The AcMPAG metabolite has also been suggested to contribute to the 
MPA related gastrointestinal toxicity.141,142 Other minor metabolites include phenolic 
and acyl glucosides, probably generated by uridine diphosphate-glucosyltransferases, 
and a 6-O-desmethyl metabolite, which is generated by cytochrome P-450 (CYP) 3A 
isoenzymes.138-140 The metabolic pathway of MPA is depicted in Figure 9. 
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Figure 9. Pharmacokinetic (PK) processes of mycophenolic acid (MPA).  
Chemical structures of MPA, the administered compounds mycophenolate mofetil (MMF) and 
mycophenolate sodium (MPS), and three metabolites are depicted. The major enzymes 
involved in generation of the 7-O-glucuronide (MPAG, major, inactive), acyl glucuronide 
(AcMPAG, minor, active) and 7-O-glucoside (MPAGls, minor, active) metabolites of MPA are 
given. Factors with potential impact on PK processes are illustrated. 
 
CsA, cyclosporine; GI, gastrointestinal; MRP2, multidrug resistance-related protein 2; UGT, 
uridine diphosphate-glucuronosyltransferase (MPAG, AcMPAG) or uridine diphosphate-
glucosyltransferase (MPAGls). 
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The MPAG metabolite undergoes extensive biliary secretion via the ATP binding 
cassette (ABC) transporter, multidrug resistance-associated protein 2 (MRP2) in 
hepatocytes.143 MPAG can be hydrolyzed back to MPA by bacterial glucuronidases in 
the intestine and then reabsorbed into the systemic circulation (Figure 9). This 
enterohepatic circulation (EHC) of MPA can be observed as secondary concentration 
peaks at 4−12 hours postdose and account for approximately 40% (range 10−60%) of 
the total MPA area under concentration-time curve (AUC).144 Other transporters, e.g. 
breast cancer resistance protein (BCRP/ABCG2) and organic anion-transporting 
polypeptides (OATP, SLCO) have also been associated with MPAG transport.145 
 
The MPA metabolites are cleared primarily by renal excretion while a small 
proportion is eliminated by the fecal route after secretion into bile.124 The terminal 
elimination half-life is estimated to be in the range of 9 to 17 hours.125,146,147 
 
The variability of MPA pharmacokinetics is large within and between individuals.144 
More than 10-fold differences have been reported for the dose-normalized MPA 
AUC0−12h.148 In addition to the mentioned impact of renal and hepatic function and 
albumin levels, factors like comorbidities, comedication, genetics and times since 
transplant might contribute to the PK variability of MPA. 
 
Drug interactions 
Concomitant intake of drugs like antacids, ferrous sulphate, cholestyramine and 
sevelamer, has been reported to impair the absorption of MPA.122,124,149,150 
Corticosteroids and rifampicin could induce the synthesis of UGT enzymes and 
possibly drug transporters and thereby increase the clearance of MPA.151-153 Exposure 
to MPA when given in combination with CsA is approximately 30−40% lower than 
when given alone or in combination with tacrolimus or sirolimus.154-158 CsA is 
reported to mediate dose-dependent inhibition of the MRP2 transporter.143,159 This 
suppresses the excretion of MPAG into bile and consequently the EHC of MPAG, 
thus reducing plasma concentrations of MPA.160 Antibiotic therapy has also been 
shown to reduce EHC in healthy individuals and transplant patients, probably 
mediated through disruption of the normal gut flora and a reduction in bacterial 
glucuronidase activity.161,162 
 
Introduction – Mycophenolic acid 
 37 
Time dependent pharmacokinetics 
The MPA pharmacokinetics is reported to change during the first months after 
transplantation.  Renal transplant patients display 30−50% lower MPA exposure 
(AUC0−12h) the first few weeks, compared to 1−6 months posttransplant.124,163,164 The 
change in MPA concentrations is multifactorial and could be related to improvement 
in renal function and hypoalbuminemia, and tapered doses of corticosteroids and 
CNIs.133,165-167 
 
Genetics 
There are considerable differences between individuals in both protein levels 
(17-fold) and enzymatic activity of UGT enzymes.168 Single nucleotide 
polymorphisms (SNPs) of the UGT1A9 gene have been associated with protein 
expression and enzymatic activity,169,170 suggesting that genetic polymorphisms might 
contribute to the variable MPA metabolism. A recent study in renal allograft 
recipients reported that a significantly higher proportion of MPA concentration 
measurements was in the low MPA target range in patients carrying the UGT1A9 
upstream SNPs −275T>A (rs6714486) and/or −2152C>T (rs17868320).171 Genetic 
variability has also been reported for ABCC2, encoding MRP2, but the clinical 
relevance is not known.172 
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1.4 Individualization of Mycophenolate Therapy 
1.4.1 Monitoring; Why, when and how? 
The use of MPA in transplantation is steadily increasing. Beneficial effects on long-
term outcomes have promoted the use in novel immunosuppressive regimens and to 
facilitate CNI or corticosteroid sparing. Over the last decade, MPA has also emerged 
as a therapy for autoimmune diseases. However, the therapeutic potential is limited by 
the narrow therapeutic window and dose limiting toxicity of MPA. The most frequent 
adverse events are gastrointestinal (GI) effects including nausea, vomiting, abdominal 
pain and diarrhea.10-13 A formulation of enteric-coated mycophenolate sodium (EC-
MPS) was launched to improve the upper GI tolerability of MPA. However, no 
significant improvements with respect to the frequency or severity of adverse effects 
were observed.173,174 Hematological toxicities, mainly leukopenia and anemia, and an 
increased risk of opportunistic infections are among other serious adverse events.10-12 
The toxicity is mainly reversed with dose reductions or temporary discontinuation of 
therapy. However, MPA dose tapering is associated with an increased risk of acute 
graft rejection in renal allograft recipients.175,176 Studies of renal, cardiac and liver 
allograft recipients reported that approximately half of the patients receiving MMF in 
combination with CsA were underexposed to MPA early posttransplant according to 
recommended target ranges,177 thus being of higher risk of rejection.175,178 
Furthermore, reaching an adequate MPA exposure might be of particular importance 
when MPA is used in CNI or corticosteroid sparing regimens. 
 
The concentration related efficacy, large PK and PD variability and narrow 
therapeutic window of MPA provide a rationale for therapeutic drug monitoring 
(TDM). Individualized MPA therapy could enhance the efficacy and minimize the 
toxicity of the drug and thereby improve outcomes in transplantation and other fields 
of immune modulation.  
 
There is a particular value for monitoring MPA therapy in the early posttransplant 
period, during major changes in immunosuppression (e.g. tapering of CNI or 
corticosteroids) and at the time of major clinical events (rejection, infection, adverse 
events or malignancy). Individualization of MPA therapy could be guided through 
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pharmacokinetic (PK), pharmacodynamic (PD) and/or pharmacogenetic approaches 
(Figure 10). 
 
Pharmacokinetic monitoring 
TDM has traditionally been pharmacokinetically oriented, using drug concentrations 
as surrogate markers for drug activity. To justify TDM, there should be a clear 
relation between the measured parameter and clinical events (toxicity, acute 
rejections). Common PK parameters include measurements at single time points, area 
under concentration-time curve (AUC) and various limited sampling strategies for 
estimation of AUC. Methods for measurement of MPA concentrations include 
immunoassays, liquid chromatography (LC) methods with UV or mass spectrometric 
(MS) detection and a novel enzymatic assay based on IMPDH inhibition.179,180  The 
immunoassays are less laborious and time consuming compared to LC methods. 
However, the antibody used in the immunoassays cross reacts with the AcMPAG 
metabolite, thus overestimating MPA concentrations.181 The LC methods are more 
specific and allow accurate determination of both free and total concentrations of 
MPA and metabolites.  
 
The potential of PK guided dosing was first demonstrated in a concentration 
controlled trial in renal transplant patients163,182 and later confirmed in studies in 
pediatric patients.164,183 The full 12-hour MPA AUC was reported to be the best 
predictor for acute rejection episodes182-184 and a therapeutic range of MPA AUC0−12h 
between 30 and 60 mg×h/L has been suggested in patients on CsA based 
immunosuppression.182 Optimal therapeutic ranges may depend on the type of 
transplant, time since transplantation, immunosuppressive regimen and the presence 
of risk factors for acute rejection and should therefore be investigated for these 
conditions. The full AUC0−12h parameter is impractical for routine monitoring and 
several limited sampling strategies are evaluated for the best estimation of MPA 
AUC0−12h. 
 
Two recent randomized clinical trials, the Fixed Dose Versus Concentration 
Controlled (FDCC) and the Apomygre, evaluated the value of TDM of MMF in de 
novo renal allograft recipients during a 12 months posttransplantation period. The 
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Apomygre trial included 137 patients receiving MMF in combination with CsA, 
corticosteroids and basiliximab. The MMF doses in the concentration controlled 
group were guided using a Bayesian estimator based on a three point limited sampling 
strategy. The concentration controlled MMF group demonstrated a reduced risk of 
treatment failure and acute rejections without any increase in adverse effects, 
supporting the use of TDM.185 In contrast, the FDCC trial (n=901) did not show any 
benefit of TDM. The patients received CsA or tacrolimus based immunosuppression 
and the MPA AUC0−12h was estimated by a three point limited sampling scheme in 
combination with a linear regression algorithm. The MPA exposure was similar 
between the groups, which might be a result of nonadherence to the recommended 
dose increments in the concentration controlled group.178 This implies that no 
difference could be expected between the groups. Both studies found an association 
between MPA exposure and acute rejection.178,185 
 
While the efficiency of MPA is associated with drug exposure, the correlations 
between PK parameters and GI toxicity or infections are poor and inconsistent, and a 
clear cutoff between effective drug exposure and the appearance of adverse effects 
has not been established.163,171,178,182 An explanation could be that the reported adverse 
effects have multiple causes. Furthermore, GI toxicity is reported to be stronger 
related to MMF dose than to MPA plasma concentrations,182 suggesting an impact of 
local GI drug exposure. This theory is supported by a substudy of the FDCC trial, 
reporting more frequent GI toxicity in tacrolimus treated patients, which probably was 
related to a greater intestinal exposure to MPA metabolites in these patients.186 
Measurements of free MPA concentration or concentrations of metabolites like 
AcMPAG have been proposed to better predict adverse effects, but the data are 
conflicting.183,186,187 Hematological toxicities are stronger correlated to MPA 
exposure, and a recent study in renal allograft recipients suggested that patients 
suffering from leukopenia or anemia might benefit from MMF dose adjustments 
based on PK measurements.171 
 
The poor correlation between MPA concentration and adverse effects, the limited 
value of PK monitoring the first days of treatment and the high interindividual 
variability of the drug target, IMPDH, indicates a potential for PD measurements as 
an alternative or supplemental approach for monitoring MPA therapy. 
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Figure 10. Monitoring of mycophenolate therapy. 
Potential approaches to improve the clinical outcomes during mycophenolate therapy.  
 
AUC, area under the concentration versus time curve; SNP, single nucleotide polymorphism  
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Pharmacodynamic measurements 
Monitoring of PD biomarkers integrates both PK and PD variability and provides 
more direct determination of the biological effects of drugs. Potential PD parameters 
of MPA efficacy include IMPDH activity, guanine nucleotides and lymphocyte 
proliferation. Different approaches and sample matrixes for PD monitoring are 
addressed in Section 1.4.2. 
 
Pharmacogenetics 
Pharmacogenetic strategies for individualization of drug therapy include genotyping 
SNPs of e.g. drug targets, metabolizing enzymes or transporters. This approach offers 
an opportunity for initial selection of drug regimen and adjustment of dosing to ensure 
adequate immunosuppression during the critical first days posttransplant. Moreover, 
genotype information is valuable in the interpretation of PK or PD data. The genotype 
is a stable characteristic and only needs to be determined once for any give gene. In 
transplanted patients, the genotype of the graft might also bee of interest.188 The 
individual drug response is determined by multiple genes and gene-to-gene 
interactions, thus haplotyping or pharmacogenomic approaches could offer better 
prediction of drug response. Microarray technology allows gene expression profiling 
at the genome level. However, these strategies require advanced methodology and 
data interpretation. Potential candidates for pharmacogenetic testing of MPA could be 
the two IMPDH isoenzymes (IMPDH1, IMPDH2), the MRP2 transporter (ABCC2) 
and UGT enzymes. However, the value of genotyping has not yet been assessed for 
MPA, and further studies are required to characterize the impact of genetics on MPA 
PK or PD (Section 1.4.3). 
 
1.4.2 Pharmacodynamic biomarkers of mycophenolate effect 
The efficacy of MPA therapy can be evaluated by drug specific and non-specific 
biomarkers. Non-specific PD parameters reflect the general activity of the immune 
system. Common biomarkers for evaluation of the overall immunosuppression 
include various lymphocyte proliferation assays, determination of lymphocyte surface 
antigens (e.g. CD11a, CD25, CD71, CD95, CD134 and CD154) and cytokine 
production.189 The methodology includes flow cytometric, reverse transcription (RT)-
PCR and ELISA techniques. Barten et al. demonstrated that inhibition of lymphocyte 
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proliferation and antigen expression by MPA correlated with MMF dose, MPA level 
and with the histologic grade of graft rejection in a cardiac transplant rat model.190 
More recently, a commercially available whole blood assay was introduced for 
assessment of overall immune function (Cylex ImmuKnowTM). The assay is based on 
measurement of ATP levels in CD4+ cells after stimulation with 
phytohemagglutinin.191 However, the assay is not specific for immune status since 
ATP levels reflect the overall energy metabolism of cells. The potential of the assay 
in transplantation is debated and needs further evaluation.192,193 Moreover, an 
interferon-γ (INF- γ) enzyme-linked immunosorbent spot (ELISPOT) assay has been 
reported to be a highly sensitive tool for assessment of primed effector/memory T 
cells.194 In renal allograft recipients, the cellular alloreactivity as measured by the 
INF-γ ELISPOT assay, correlated with acute rejection and renal functional 
impairment posttransplant.195 Indeed, these findings need to be confirmed in 
prospective studies and larger cohorts of patients. 
 
Measurement of the catalytic activity of IMPDH is investigated for more specific 
characterization of MPA effects. The techniques for determination of IMPDH activity 
comprise radioassays determining the IMPDH catalyzed conversion of radiolabelled 
substrate196 and several LC assays measuring the XMP production rate using UV or 
mass spectrometry (MS) for product detection.197-202 The initial assays determined 
IMPDH activity mainly in whole blood. However, as lymphocytes are the principal 
targets for immunosuppressive effects, IMPDH measurements in these cells are 
considered to be the most appropriate to ensure adequate immunosuppression 
(Sections 1.4.3 and 1.4.4). Several LC assays are validated for IMPDH analysis in 
isolated peripheral blood mononuclear cells (PBMCs).197-199 However, the isolation 
and pretreatment of cells might influence the measured IMPDH activity.198,203 
Another IMPDH assay, based on the method published by Albrecht et al., was 
developed for analysis in isolated CD4+ cells. Intracellular MPA concentrations were 
restored after cell isolation to avoid potential wash-out of MPA during the cell 
preparation steps.201 None of these activity measurements can distinguish between the 
IMPDH isoenzymes. 
 
Gene expression assays have been used to characterize the relative importance of the 
isoenzymes, and furthermore to explore the mechanisms of IMPDH regulation. 
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Traditionally methods for determination of gene expression include Northern blotting 
and qualitative/competitive RT-PCR. The more recently introduced real-time RT-
PCR technology allows more accurate quantification of mRNA over a broad dynamic 
range. However, the reliability of the results highly depends on assay design, 
optimization and the quantification strategy. Vannozzi et al. presented a real-time RT-
PCR assay for quantification of IMPDH2 mRNA in human lymphocytes normalized 
to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The 
calculations did not include correction for PCR efficiency and only limited validation 
of the method was presented.204 Another quantitative RT-PCR assay determined the 
expression of both IMPDH isoforms in various cells in sheep. Amplification products 
were monitored by SYBR Green I and the expression of target genes was normalized 
to a single reference gene, beta-actin.205 We developed and validated a real-time RT-
PCR assay for specific quantification of IMPDH1 and IMPDH2 in human blood cells 
(Paper I). Expression of the target genes were normalized to a reference gene index 
(RGI) as described in Section 3.1.  
 
Since the major effects of MPA are mediated through alterations of guanine 
nucleotide levels, measurement of guanine nucleotides could represent a biomarker 
closer related to MPA efficiency than IMPDH levels. In multiple myeloma patients 
treated with MMF, a positive correlation was observed between depletion of 
intracellular dGTP and clinical response.206 However, the relation between guanine 
nucleotide levels and clinical outcome in transplantation remains to be characterized. 
Furthermore, the relevance of the different nucleotide pools for immunosuppressive 
action is not definitively determined. Following administration of single MMF doses, 
no immediate reduction of guanine nucleotides (GDP and GTP) was observed in 
CD4+ cells from healthy individuals.207 However, this might not reflect the response 
in populations of activated cells during repeated dosing.208 
 
Based on the current knowledge, no conclusions can be drawn as to which are the 
most appropriate PD biomarkers and how best to monitor them. 
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1.4.3 IMPDH and clinical outcome 
The high variability of IMPDH activity between individuals prior to transplantation 
emphasizes the rationale for individualized MPA exposure. Although IMPDH 
measurements are not implemented in clinical routine yet, several retrospective 
investigations in MMF treated patients support the clinical potential of IMPDH 
monitoring.  
 
In renal transplant patients, high pretransplant IMPDH activity in PBMCs was 
associated with acute rejection episodes.209 This is in agreement with our finding that 
high pretransplant IMPDH2 expression in CD4+ cells predicted acute rejection 
episodes (Paper II). Furthermore, high IMPDH activity (AUC0−12h) in PBMCs at day 
6 posttransplant was significantly associated with acute rejection in renal allograft 
recipients, while no correlation was observed for MPA exposure.210 Another recent 
study reported less IMPDH inhibition in lymphocytes from patients with acute 
rejection during the first week posttransplant compared to patients without 
rejection.211  
 
The variable activity of this enzyme could also explain some of the adverse effects. 
Glander et al. reported that low pretransplant IMPDH activity in PBMCs predicted 
MMF dose reduction because of intolerable adverse events.209 In contrast, a study in 
liver transplant patients on MMF therapy demonstrated a trend towards more 
gastrointestinal and hematological complications with elevated IMPDH2 gene 
expression in PBMCs.204 
 
These findings suggest that PD monitoring by IMPDH measurements might address 
some of the limitation of PK monitoring. Indeed, further studies are needed to 
characterize the relation between IMPDH parameters and the clinical outcome before 
prospective intervention studies based on IMPDH monitoring may be initiated. 
Assays should be standardized to allow comparisons between studies.  
 
IMPDH and immune activity 
The relation between IMPDH levels in lymphocytes or mononuclear cells and 
outcome after transplantation might be explained by the immune status of the patient. 
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The mechanisms of immune activation and allograft rejection involve the expression 
and regulation of multiple genes. Activation of T cells is associated with a 
considerable increase in IMPDH enzyme activity, as well as upregulation of IMPDH 
1 and 2 gene expression (Figure 11).35 In renal transplant patients, up to 20-fold 
upregulation of predose IMPDH1 expression was observed in PBMCs during acute 
rejection episodes.212 Devyatko et al. demonstrated a close correlation between 
IMPDH predose activity in PBMCs and the proportion of activated (CD38+) CD8+ 
cells in heart transplant patients, suggesting that IMPDH plays a role in the regulation 
of CD8+ T cell activation.213 Diabetic renal transplant patients generally have lower 
innate immune status than non-diabetic transplant patients.214,215 This could explain 
the lower IMPDH activity that was observed in PBMCs from diabetic compared to 
non-diabetic renal transplant patients.215 The activity or gene expression of IMPDH 
might thus provide a surrogate marker for cellular immunity (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Schematic illustration of T cell activation and IMPDH upregulation. 
The first exposure to foreign antigens may induce a primary immune response. Naïve T cells 
are activated by professional antigen-presenting cells (APCs) in lymphoid tissue. The 
subsequent proliferation and differentiation into effector T cells is driven by interleukin-2 (IL-2) 
and requires an upregulation of IMPDH activity. In addition to the generation of relatively 
short-lived effector cells, some cells become long-lived memory T cells, which may be 
sustained by cytokines.  
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The immune status pretransplant could be influenced by e.g. dialysis, infections, 
previous pregnancies, blood transfusions and previous transplantations. Exposure to 
dialysis is associated with non-specific cellular activation, particularly of T cells, that 
might contribute to increased alloreactivity and hence the risk of rejection.194,216 This 
is in agreement with our observations that the risk of rejection seemed to be higher 
among patients with dialysis pretransplant compared to patients without (50% versus 
21%, ns, Paper II).  
 
Genetic polymorphisms 
Recently, polymorphisms within the IMPDH1 and IMPDH2 genes have been 
suggested to impact baseline IMPDH activity and outcomes  after transplantation 
(location of variants in Figure 4, Section 1.2.2).217-219 Wang et al. reported two 
intronic IMPDH1 single nucleotide polymorphisms (SNPs; rs2278293 and 
rs2278294) that were significantly associated with acute rejection episodes in renal 
transplant patients receiving MPA therapy.217 Grinyo et al. demonstrated that the 
presence of at least one IMPDH2 3757T>C (rs11706052) allele tripled the odds for 
developing rejection within 12 months posttransplant.219 The association between the 
genetic variants and posttransplant outcome may be correlated with enzyme activity. 
A recent study in renal allograft recipients showed that the presence of an IMPDH2 
3757T>C allele correlated with significantly higher IMPDH activity in PBMCs 
during MPA exposure.220 A nonsynonymous c.787C>T variant (L263F) of IMPDH2 
resulted in a reduction of enzyme activity to 10% of wild type activity. The allele 
frequency in a cohort of transplant patients was 1%, and the variant genotype was 
suggested to predispose for MPA related leukopenia.217,218  
 
The clinical impact of the gene variants needs further characterization and evaluation 
before potential implementation in e.g. dosing algorithms for individualized MPA 
exposure. 
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1.4.4 Potential induction of IMPDH during MPA therapy 
The pharmacodynamics of MPA has been reported to change with time in transplant 
patients. The findings are indeed conflicting and seem to depend on methodology, cell 
type, cell cycle status and degree of MPA exposure.  
 
Whole blood and erythrocytes 
Several studies report an induction of IMPDH activity in whole blood and 
erythrocytes during prolonged MMF therapy. In heart transplant patients, long-term 
MPA therapy (>1 year) was associated with an elevation of predose IMPDH activity 
(5-fold), GTP concentrations (2-fold) and to a lesser extent HPRT activity in 
erythrocytes.221 Similar findings were reported by Goldsmith et al., demonstrating 
3−4 fold higher GTP levels in predose erythrocyte samples from renal transplant 
patients receiving MMF (>3 months) compared to patients with AZA.222 An increase 
in predose IMPDH activity was also reported in whole blood samples from renal 
transplant patients.203,223 Following an immediate reduction early posttransplant, the 
enzyme activity increased gradually and was 5 times higher than pretransplant levels 
approximately 40 days posttransplant.223 Despite the elevated predose activity, 
IMPDH activity was considerably suppressed within the dose intervals.203,223 In 
another study in renal transplant patients, we observed an elevation of predose 
IMPDH 1 and 2 gene expression in reticulocytes (Figure 15, Section 4.2), which 
could be related to the MMF treatment (Paper II). The increase started the second 
week posttransplant and was accompanied by a similar rise in whole blood activity. 
This implies that the gradual upregulation of predose activity in whole blood might 
involve an induction at the transcriptional level in the early differential stages of 
erythrocytes. The IMPDH predose activity in erythrocytes is also reported to be 
induced by ribavirin, another IMPDH inhibitor. In immunodeficient children, 
considerable increments of IMPDH predose activity (up to 30-fold) were observed 
3−4 weeks after introduction of ribavirin antiviral therapy.202  
 
A dose interval study in renal transplant patients on short-term (<1 year) versus long-
term (>2 years) MMF treatment demonstrated that the inhibitory effect of MPA on 
whole blood IMPDH activity was reduced in the long-term treated patients. With 
prolonged therapy, individual patients demonstrated only weak inhibition and 
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subsequent increases of activity reaching 5 times the predose levels.224 Similar 
findings were also reported in a later study, showing 2- to 4-fold induction of whole 
blood activity postdose in patients on prolonged (18−24 months) MMF therapy.212 
Despite the induction within dose intervals, no alteration was observed in predose 
activity.212 The rapid and transient induction of IMPDH activity suggests a 
considerable influence of IMPDH in nucleated cells. The authors reported that 
IMPDH in mononuclear cells accounted for 50% of the measured whole blood 
activity.212 Langman et al. did not report any induction of enzyme activity. Predose 
IMPDH activity in whole blood was comparable between MMF and AZA treated 
patients (>2 years posttransplant). Following dose, an immediate and reversible 
inhibition of IMPDH activity was observed only in the MMF patients. With respect to 
guanine nucleotides, intracellular levels of GMP and GDP were lower, while the GTP 
concentrations were higher in the MMF group compared to AZA patients.225 Indeed, 
both MMF and AZA might influence purine nucleotide levels and thereby complicate 
the interpretation of these findings.  
 
Mononuclear cells 
In contrast to the elevation that was observed for predose IMPDH activity and GTP 
levels in erythrocytes and whole blood, the corresponding parameters seem to be 
relatively stable or declining with prolonged MPA therapy in various populations of 
mononuclear cells. In heart transplant patients switched from AZA to MMF, the 
IMPDH predose activity in PBMCs was significantly reduced after 3, 6 and 12 
months on MMF therapy while MPA C0 remained stable.226 No significant alterations 
were observed for concentrations of GTP in the corresponding samples. This could be 
explained by a concomitant increase in HPRT activity, which maintains the 
intracellular purine nucleotide pools.226 Similar results were observed by Sankatsing 
et al. in renal transplant patients on MMF therapy. Predose levels of dGTP and GTP 
were stable during the 8 weeks posttransplant follow-up. Despite this, ex vivo 
stimulated T cell proliferation was inhibited. Comparable findings were reported in 
HIV-1 infected patients receiving MMF.227 In contrast, Jagodzinski et al. reported a 
significant decrease in GTP and total guanine nucleotide pools in PBMCs from renal 
transplant recipients with MMF therapy compared to dialysis patients and healthy 
controls. Guanine nucleotide concentrations were similar between patients with MMF 
treatment for less and more than 6 months.208   
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Considering dose interval studies of renal transplant patients, Sanquer et al. reported 
transient inductions of IMPDH1 expression in PBMCs after MMF intake. The 
induction was highest three months after transplantation (mean 236%, SD ± 229%, 
compared to predose), but was considerable throughout the two years observation 
period. The predose samples demonstrated higher IMPDH1 expression the first three 
months, while expression was stable from 6 to 24 months posttransplant. Expression 
of IMPDH2 was stable throughout the study period, but increased postdose at month 
24 (mean 50%, SD ± 45%).212 This is in agreement with our findings in a study of 
patients on belatacept or CsA based immunosuppression, including MMF (Paper IV). 
With increasing time since transplantation, we observed transient postdose inductions 
of IMPDH1 gene expression and IMPDH activity in CD4+ cells (Figure 17, Section 
4.4). The rapid and transient induction observed in nucleated cells contrasts the 
gradual elevation in erythrocytes, which may originate from an induction in earlier 
differentiation stages that persists during erythrocyte maturation.  
 
Other dose interval studies, however, did not observe altered PD response in 
mononuclear cells with time. Glander et al. reported no significant difference in 
IMPDH inhibition in PBMCs from dialysis patients receiving their first MMF dose 
versus cardiac transplant patients on prolonged MPA therapy (>1 year),228 however 
such comparisons across populations must be interpreted cautiously. Another study in 
renal transplant patients also demonstrated an inverse relation between MPA 
concentration and IMPDH activity, with a mean inhibition of 87%, more than a year 
posttransplant.229 Furthermore, a study comparing EC-MPS and MMF formulations in 
renal transplant patients demonstrated considerable inhibition of IMPDH activity 
within the dose interval after more than 3 months of MPA therapy.230 
 
Feedback regulation 
Expression of the IMPDH genes is suggested to be regulated by guanine nucleotides 
through negative feedback mechanisms in human cells (Figure 12 and Section 
1.2.2).35,40 The apparent induction of IMPDH activity could thus be related to 
increased gene expression. However, feedback regulation at the enzymatic level 
cannot be excluded (Section 1.2.1).  
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The regulation of IMPDH during MPA exposure has been studied in various human 
in vitro cell models. Glesne et al. examined the effects of guanosine and MPA on 
IMPDH mRNA in promyelocytic and melanoma cell lines. Guanosine 
supplementation increased the intracellular guanine nucleotide levels and 
subsequently reduced IMPDH expression whereas exposure to MPA reduced guanine 
nucleotide levels and increased the IMPDH mRNA levels.34 IMPDH protein levels 
were influenced in a similar manner. The authors suggested IMPDH to be regulated at 
the posttranscriptional level, and that the regulation occurred through alterations of 
guanine nucleotides rather than deoxyguanine nucleotides.34 An inverse regulation in 
response to guanine nucleotides was also observed in another study in cultured human 
acute T lymphoblastic leukemia (MOLT-4) cells. Following MPA exposure (0.15 and 
0.5 µmol/L, 72 hours), a reduction of GTP (35% of control) levels was observed and 
accompanied by increased expression of IMPDH1 (40%) and IMPDH2 (2-fold).53 
Dayton et al. investigated normal human T cells during ex vivo exposure to 
mizoribine, an IMPDH inhibitor, and guanosine (12 and 24 hours). Inhibition of 
IMPDH activity resulted in an upregulation of IMPDH2 expression (3-fold), probably 
mediated through reduced guanine nucleotides.35 On the other hand, a study in ex vivo 
stimulated PBMCs and three different transformed cell lines did not demonstrate any 
significant changes in IMPDH 1 or 2 mRNA or protein levels after exposure to MPA 
(<1 µmol/L, 72 hours).58 The relationship between guanine nucleotides and 
expression of IMPDH isoforms is poorly characterized in vivo in humans. In a study 
of healthy individuals exposed to MPA, we observed that IMPDH1 expression tended 
to be inversely related to GTP concentrations. Indeed, the purine nucleotide responses 
were variable and the correlation was not statistically significant (Paper III). 
 
Interpretation of the relation between MPA exposure, IMPDH activity and finally 
guanine nucleotide pools might be complicated by various degrees of compensating 
mechanisms like induction of the IMPDH isoenzymes and HPRT. Furthermore, the 
most relevant nucleotide pools with respect to the IMPDH regulation remain to be 
elucidated.  
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Figure 12. Negative feedback regulation of the IMPDH genes. 
Inhibition of inosine 5’-monophosphate dehydrogenase (IMPDH) by mycophenolic acid (MPA) 
reduces de novo synthesis of guanine- and deoxyguanine nucleotides (GN and dGN, 
respectively). This could attenuate a suppressive mechanism of GN/dGN on gene expression 
and consequently induce the expression of IMPDH1 and/or IMPDH2. The relative 
contributions of de novo (via IMPDH) and salvage pathways differ between cell type and cell 
cycle status. Arrows represent stimulation while T-bars represent inhibition. 
 
indicates steps that are suppressed by MPA.   
 
Clinical implications 
The IMPDH activity in whole blood is probably predominated by erythrocytes, which 
constitute the largest blood cell population. Alterations in blood cell numbers and 
populations might also impact whole blood measurements. Furthermore, the clinical 
relevance of the observed enzyme induction of erythrocyte predose activity is not 
known. Thus, IMPDH measurements in lymphocytes might better predict MPA 
efficacy. Activated lymphocytes play a pivotal role in allograft rejection and are 
among the target cells for MPA effects. Indeed, the activity in the general population 
of circulating lymphocytes or mononuclear cells might not reflect the IMPDH status 
in a relatively low fraction of activated, proliferating lymphocytes. 
  
The requirement of guanine nucleotides is considerable higher in proliferating versus 
resting, non-proliferating lymphocytes and this is reflected in different basal levels of 
IMPDH activity. It could be speculated that inhibition of IMPDH in cells with 
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relatively low basal IMPDH activity to a higher degree initiates compensating 
mechanisms, like induction of IMPDH and HPRT enzymes, to maintain the guanine 
nucleotide levels that are required for constitutive processes. The relative importance 
of IMPDH versus HPRT enzymes depend on cell type. Such induction has been 
reported in vivo and in vitro and may completely mask the inhibition of IMPDH 
activity and even induce IMPDH and guanine nucleotide levels. Budde et al. reported 
that two dialysis patients with low basal IMPDH demonstrated a small elevation of 
IMPDH protein 6 hours after the first MMF dose.231 In a study of healthy individuals, 
we also observed an “overshoot” of IMPDH activity and gene expressions appearing 
8−24 hours after administration of MMF 1000 mg (Section 4.3 and Paper III). In 
contrast, IMPDH inhibition in cells with higher enzyme levels might not suppress 
guanine nucleotide levels sufficiently to induce IMPDH and/or HPRT. Alternatively, 
even if compensatory mechanisms are induced, this might not be adequate to supply 
the required guanine nucleotides in proliferating cells. Hence, MPA may increase 
IMPDH in resting cells and still inhibit the proliferation of activated cells. This could 
provide an explanation for why induction of IMPDH does not translate into reduced 
clinical efficacy of MPA. This present hypothesis is further supported by studies in 
renal transplant and HIV-1 infected patients on MMF therapy. Although dGTP and 
GTP levels in PBMCs were stable, ex vivo induction of T cell proliferation was 
inhibited.227,232  
 
The apparent loss of inhibitory action of MPA on IMPDH in PBMCs and CD4+ cells 
within dose intervals might thus reflect an effect in a population of mainly non-
proliferating cells and may not be relevant for MPA efficiency. Indeed, further studies 
are needed to explain these findings. The hypothesis could be addressed by relating 
the IMPDH results to lymphocyte activation status (e.g. by flow cytometric 
assessement) and by investigations of specific cell populations.  
 
The activity of IMPDH depends on cell type, cell cycle and differentiation status. 
Hence, the results of the reported studies might be impacted by the cell subsets 
investigated. Furthermore, the contrasting findings between studies could be 
influenced by differences in methodology (e.g. Northern blotting versus real-time 
PCR), control groups (AZA treated, dialysis patients and healthy individuals), 
comedication and time since transplantation.  
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The feedback regulation of the IMPDH genes seems to differ from the regulation in 
response to inducers of cell proliferation and growth. While both isoforms are 
considerably upregulated with lymphocyte activation, the MPA induced regulation in 
PBMCs and CD4+ cells was most pronounced for IMPDH1 (Paper IV).212 This might 
be related to different functions of the isoenzymes. 
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2. Objectives of the Thesis 
 
In the process of optimizing MPA therapy in transplanted patients, better knowledge 
of the pharmacodynamic-pharmacokinetic relations of MPA is warranted. The main 
objective of this thesis was to characterize the two IMPDH isoenzymes during 
exposure to MPA.  
 
Specific objectives of the projects were as follows: 
 
2.1 Paper I 
The aim of the first project was to establish and validate a method for reliable 
quantification of IMPDH1 and IMPDH2 gene expression in human blood cells to 
explore the regulation of the IMPDH isoenzymes.   
 
2.2 Paper II 
The primary objective of this study was to investigate whether a reported induction of 
whole blood IMPDH activity in renal allograft recipients223 was due to altered gene 
expression, and to determine the relative contributions of IMPDH1 and IMPDH2 in 
relevant blood cell populations. A second objective was to identify possible 
associations between the IMPDH expression in transplanted patients and factors like 
acute rejection episodes, dialysis pretransplant or the current immunosuppressive 
treatment, including MPA.  
 
2.3 Paper III 
The primary goal of this study was to investigate the regulation of IMPDH1 and 
IMPDH2 in blood cells from healthy individuals during in vivo exposure to MPA. A 
secondary objective was to investigate the gene expressions in association with the 
corresponding IMPDH activities and concentrations of MPA and purine nucleotides.  
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2.4 Paper IV 
The aim of this study was to investigate MPA pharmacokinetics and 
pharmacodynamics in recipients of extended criteria donor (ECD) renal allografts, 
receiving MMF in belatacept or CsA based immunosuppressive regimens. 
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3. Methods 
3.1 Paper I 
Development and validation of the real-time RT-PCR assay was based on whole 
blood and isolated cells from healthy volunteers and patients. Furthermore, the assay 
was adapted for measurement in cultured lymphoblasts. PAXgene Blood RNA 
Tubes® provided immediate stabilization of the expression profile in whole blood. 
Paramagnetic beads with CD4 antibodies were used to isolate CD4+ cells from EDTA 
blood. Red blood cells (reticulocytes and erythrocytes) were separated from whole 
blood by filtration through a column consisting of α-cellulose and microcrystalline 
cellulose.233  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Overview of the steps of the gene expression assay. 
 
Total RNA was extracted from lysed blood cells on the automated MagNA Pure® 
instrument. Concentration, purity and integrity of total RNA was evaluated by 
spectrophotometry on the NanoDrop® ND-1000 and electrophoresis on the Agilent 
Bioanalyzer® 2100. Reverse transcription (RT) was performed in a separate step, 
preceding real-time PCR on the LightCycler® 1.0 instrument (Figure 13). Reaction 
parameters were optimized for each step and the pre-PCR steps included a constant 
Lysate of whole 
blood/isolated cells
total RNA
cDNA
Automated RNA isolation:
MagNA Pure LC
Reverse transcription:
thermal block cycler
Real-time amplification:
LightCycler 1.0/480 
IMPDH1
IMPDH2
ALAS1
B2M
RPL 13A (G6PD)
ReferenceTarget
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concentration of carrier RNA (MS2 RNA). The optimized RT was performed with 
Transcriptor reverse transcriptase, using random hexamer primers. Target and 
reference genes were amplified in separate reactions and amplification products were 
monitored by SYBR Green I during the optimizing stages, whereas hybridization 
probes were used for quantification. Gene specific primers and hybridization probes 
were designed using OLIGO 6.60 software and the LightCycler Probe Design 
software combined with manual evaluation. Primer and probe target sequences were 
checked for possible homologies with other sequences by Basic Local Alignment 
Search Tool (BLAST) searches. The approximate locations of the target sequences are 
illustrated in Figure 4 (Section 1.2.2). 
 
Quantification 
Five housekeeping genes, delta-aminolevulinate synthase1 (ALAS1), beta-2-
microglobulin (B2M), glucose-6-phosphate dehydrogenase (G6PD), hypoxanthine 
phosphoribosyltransferase (HPRT1) and hydroxymethylbilane synthase (HMBS; 
previous name porphobilinogen deaminase), were evaluated as potential references 
for relative quantification. The former three genes were selected for normalization 
based on pilot data. However, further evaluations demonstrated regulation of G6PD in 
CD4+ cells. This gene was therefore omitted as a reference in these cells and 
subsequently replaced by ribosomal protein L13a (RPL 13A).  
 
The quantification principle was as follows: Relative concentrations of each target 
(IMPDH1 and IMPDH2) and reference (ALAS1, B2M and RPL 13A (or G6PD)) gene 
were calculated by the obtained crossing point (Cp) and the gene specific PCR 
efficiency (E) as in Equation 1. The expression of each target gene was calculated 
relative to the geometric mean expression of the selected reference genes (Equation 
2). This ratio was further normalized to the corresponding ratio calculated for the 
calibrator (Equation 3). The calibrator normalization corrects for different detection 
sensitivities of the target and reference amplicons and provides a constant calibrator 
point between PCR runs. Furthermore, a gene specific standard (104 copies) was 
included to serve as a positive control and allow estimation of absolute template 
concentrations using preformed calibration curves. Relevant software is presented in 
Section 3.6. 
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The assay was validated according to specificity, sensitivity, limits of detection and 
quantification, dynamic range and imprecision (within and between assay). 
 
3.2 Paper II 
This was a prospective descriptive study of 30 adults receiving renal allograft from a 
living donor. The immunosuppression included MMF for 25 of the patients. Blood 
samples were collected on three occasions preceding transplantation, and predose on 
eight occasions during the first two weeks posttransplant.  
 
The validated assay from Paper I was used to determine the gene expression of 
IMPDH 1 and 2 in whole blood, isolated CD4+ cells and reticulocytes. The IMPDH 
activity was determined in CD4+ cells and whole blood cells by LC-UV as described 
elsewhere.197,201 Intracellular MPA was removed from the CD4+ cells to determine 
the basal IMPDH activity. Predose plasma concentrations of MPA were determined 
by LC-UV,234 while whole blood concentrations of CsA (2 hours postdose, C2) and 
tacrolimus (predose, C0) were monitored using immunoassays.  
 
3.3 Paper III 
Five healthy human volunteers were included in a crossover study involving different 
MMF doses. Blood was sampled predose (−24 and 0 hours) and at 1, 2, 4, 6, 8, 12 and 
Relative expression:
Calibrator normalized
(TG /RGI)sample
(TG /RGI)calibrator
Relative concentration:               [ gene ] = E −Cp (1)
(3)
(2)
√
3 ([ ALAS1 ] x [ B2M ] x [ RPL 13A or G6PD])
[ IMPDH1 ] or [ IMPDH2 ]
Relative expression:
(TG/RGI)
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24 hours postdose for each of the single doses of 100, 250, 500 and 1000 mg MMF. A 
12-hour baseline control interval without MPA was investigated for each individual 
with sampling every two hours.  
 
The gene expressions of IMPDH 1 and 2 were quantified in CD4+ cells and whole 
blood as described for Papers I and II except that  ribosomal protein L13a (RPL 13A) 
replaced G6PD as a reference. The IMPDH activity was determined in lysates of 
CD4+ cells as described in Paper II except that intracellular MPA concentrations were 
restored in CD4+ cells by incubating the isolated cells in filtrated plasma originating 
from the same sample.201 Purine nucleotides (GDP, GTP, AMP, ADP and ATP) were 
quantified in CD4+ cells by reversed-phase anion-exchange LC-UV as described 
elsewhere.207,208  
 
3.4 Paper IV 
The MPA PK and PD study was a non-sponsored substudy in patients included in the 
BENEFIT-EXT multicentre trial.  Seven adult renal transplant patients were enrolled 
at Rikshospitalet University Hospital. The patients received grafts from extended 
criteria donors, defined as donor age above 60 years, donor age above 50 years and 
other donor co-morbidities, cold ischemia time above 24 hours or donation after 
cardiac death. Patients were randomized into three arms with CsA in one arm and 
belatacept (less intensive or more intensive, respectively) in the two others. 
Additional immunosuppression consisted of MMF 1000 mg twice daily, 
corticosteroids and induction therapy with basiliximab. Samples were collected at one 
occasion before transplantation and for 9-hour profiles at approximately 1, 2 and 13 
weeks posttransplant.  
 
The IMPDH activity in CD4+ cells (after reconstitution of MPA levels) and 
concentrations of MPA and CsA (C0) were determined as described in Papers II and 
III. The gene expression assay presented in Paper I was adapted to the LightCycler® 
480 instrument allowing higher sample throughput. The geometric mean expression 
of ALAS1, B2M and RP L13A was used for normalization of IMPDH1 and IMPDH2 
expressions. Absolute quantification of T cell subsets, defined by the markers CD3, 
CD4, CD8, CD45RA and CD45RO, was performed by flow cytometric analyses on 
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the FACS Calibur® instrument using TruCount® tubes and a direct staining 
procedure. 
 
3.5 Ethics 
The studies in Papers II-IV were approved by the Regional Committee for Medical 
Research Ethics and all participants signed an informed consent form. 
 
3.6 Data Analysis and Statistics 
Results of the RT-PCR assays were analyzed using the LightCycler software v.3.5 
and LightCycler 480 software v.1.5. The target gene expressions were normalized to 
an index comprising three reference genes using the Relative Expression Software 
Tool v.2 (REST-384) and LightCycler 480 software v.1.5. Calculations were also 
performed with the LightCycler Relative Quantification Software v.1. Flow 
cytometric data were analyzed using the CellQuest software. Data were presented as 
median (range) unless otherwise specified. 
 
Statistical analyses were performed using SPSS versions 13, 15 and 16. Since our data 
involved a limited number of observations and were not always normally distributed, 
the non-parametric Wilcoxon signed rank test and Mann-Whitney U test were applied 
for statistical analysis of paired and independent data, respectively. Statistical 
significance was considered at P≤0.05. 
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4. Results and Discussion 
4.1 Paper I 
The present assay was the first RT-PCR assay for specific mRNA quantification of 
both human IMPDH 1 and 2, normalized to a reference gene index (RGI). Previous 
reported gene expression methods for IMPDH were Northern blotting assays and two 
published real-time RT-PCR assays that normalized target gene expression to a single 
reference gene (Section 1.4.2).204,205 
 
The assay was developed primarily for gene expression measurements in transplanted 
patients. Variations in cell numbers and populations, because of immunosuppressive 
therapy or immune activation (e.g. during rejection episodes) could result in variable 
RNA yield and gene expression. Quantitative real-time RT-PCR is a sensitive method 
that allows measurement of low amounts of mRNA. However, substantial assay 
validation is required to ensure reliable gene expression results. 
 
Sample materials 
The present method was adapted for investigations in whole blood, CD4+ cells and 
reticulocytes, as well as cultured cells. Lymphocytes, and CD4+ cells in particular, 
play a pivotal role in graft rejection, and are among the main target cells for MPA 
effects (Section 1.4.2). Erythrocytes constitute the largest population of blood cells 
and probably dominate the whole blood IMPDH enzyme activity. Expression in 
reticulocytes, which contain some preformed mRNA, could provide a sensitive 
indicator for changes in the IMPDH expression and activity of erythrocytes since 
reticulocytes represent the most newly formed population.  
 
Reference genes 
Normalization of the target gene expression to an expression ratio of several reference 
genes compensates for variations in the sample amount, RNA recovery, RNA 
integrity, efficiency of cDNA synthesis, presence of inhibitors and differences in the 
overall transcriptional activity of the tissues or cells analyzed. The selection of 
suitable reference genes is an important prerequisite to obtain reliable gene expression 
results. Reference genes should display highly uniform expression across the 
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investigated cells, developmental phases, environments and experimental treatments. 
However, no single gene can be defined as an omnipotent reference for a wide variety 
of biologic systems, and several potential genes should be validated to find an optimal 
set of reference genes for each experimental system. To strengthen the accuracy of the 
IMPDH assay, we normalized the gene expression of the target genes to a geometric 
mean of three reference genes; a reference gene index (RGI). The reference genes 
were selected among ubiquitously expressed genes from different functional classes to 
reduce the influence of possible regulation. Measurement of multiple reference genes 
with each experiment allowed ongoing validation of the reference genes, thus 
controlling for variables that might not have been accounted for in the initial 
validation. Although initial investigations suggested stable expression of G6PD in our 
samples from transplant patients, further validation revealed regulation of this gene in 
CD4+ cells. Expression data of G6PD were therefore omitted from the calculation of 
gene expression in these cells, and RPL 13A was included as reference in the 
subsequent studies. The regulation of G6PD was particularly pronounced the first 
days posttransplant and could be attributed to high-dose corticosteroids, the 
transplantation itself or to potential immune responses. Figure 14 illustrates the 
consequences of relating target gene expression to a coregulated G6PD gene.   
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Impact of reference gene selection. 
Gene expression of IMPDH1 in CD4+ cells from a renal transplant recipient when separately 
normalized to the expression of three potential reference genes; aminolevulinate delta-
synthase 1 (ALAS1), beta-2-microglobulin (B2M) and glucose-6-phosphate dehydrogenase 
(G6PD). 
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Validation 
All samples were stabilized within an hour after sampling. RNA integrity numbers 
(RIN) showed isolation of intact RNA and the 260/280 nm absorption ratios (>1.9) 
indicated pure samples. The RT step is reported to be highly variable.235 Linear RT 
reactions (5×102−5×106 RNA copies) were obtained by the addition of carrier RNA 
(MS2 RNA) and using stable conditions for RNA isolation and the following RT step.  
 
The high level of sequence identity between the two IMPDH isoforms, and also to 
several IMPDH1 derived pseudogenes, emphasized the need for careful selection of 
PCR primers. Specific quantification of target sequences was further ensured by using 
gene specific hybridization probes for real-time monitoring of amplification products. 
The specificity of the assay was confirmed by gel electrophoresis, melting curve 
analysis, sequencing of amplification products and inclusion of negative controls.  
 
Calibration curves were linear over a dynamic range of at least six orders of 
magnitude (starting concentrations of 106 to 10 templates). Repeated generation of the 
calibration curves resulted in coefficients of variation (CVs) <1.7% and <0.8% for 
slope and intercept. The linearity of the calibration curves indicated constant 
amplification efficiencies over the concentration range studied, confirming minimal 
influence of PCR inhibitors. PCR efficiencies for IMPDH 1 and 2 were 2.03 and 1.99, 
while the efficiencies for ALAS1, B2M and G6PD were 1.99, 1.99 and 1.96, 
respectively. The gene specific PCR efficiencies were included in the calculations of 
relative expressions. 
 
A majority of gene expression assays report imprecision levels calculated on the basis 
of Cp values. The log-linear inverse relationship between concentrations and Cp 
values implies that CVs based on relative concentrations will be nominally higher 
than CVs based on Cp values. We quantified the imprecision in terms of relative 
concentrations and the final normalized ratios, which are directly applicable and 
relevant for the interpretation of the results. Within-run and total imprecision were 
<25%, which may be an acceptable limit in this type of assay. Repeated analysis of 
the calibrator sample, already included in each run, demonstrated the stability of the 
cDNA material over a two year period. The total between-day RT-PCR CVs were 
10.4% and 13.4% (normalized to calibrator) for IMPDH 1 and 2 respectively. Assay 
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sensitivity was confirmed by the slopes of the linear regression curves used to 
measure the dynamic range. The detection limit (LOD) was 10 templates per reaction, 
while the lower limit of quantification (LLOQ) was set to 103 templates per reaction 
since lower concentrations resulted in a significant increase in imprecision (CV) from 
<12% to >26%.  
 
The presented assay allowed specific and precise quantification of IMPDH 1 and 2 
gene expression in blood cells from healthy individuals and transplant patients 
receiving immunosuppressive therapy. This offers an insight into the regulation of the 
two isoenzymes that might be important for immunosuppressive therapy as well as for 
disease states, like malignancies. The assay was later adapted for analysis on the 
LightCycler® 480 instrument, thereby allowing higher sample throughput.    
  
4.2 Paper II 
This is the first study of IMPDH 1 and 2 expression in relation to IMPDH activity in 
different blood cell populations from renal allograft recipients pre- and posttransplant.  
Twentyfive patients received immunosuppression with MMF while 5 patients without 
MMF treatment were included as controls for MPA effects. Acute rejection episodes 
were reported for 11 (37%) patients during the follow-up and were treated with 
methylprednisolone (iv).  
 
Both IMPDH isoforms were expressed in all samples. The interindividual variability 
of IMPDH levels was large, demonstrating up to 8-, 3- and 17-fold differences in 
pretransplant gene expression for whole blood, CD4+ cells and reticulocytes, 
respectively. With respect to pretransplant enzyme activity, up to 17-fold and 41-fold 
differences were observed in whole blood and CD4+ cells, respectively. The gene 
expressions were relatively stable within individuals before the initiation of 
immunosuppressive therapy. 
 
Regulation of IMPDH the first days posttransplant 
The transplantation and initiation of immunosuppressive therapy was associated with 
median 50%, 57% and 88% upregulation of IMPDH1 expression in whole blood, 
CD4+ cells and reticulocytes, respectively (n=30, P<0.001). The increase was 
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followed by a gradual reduction the first week posttransplant nearly reaching baseline 
expression for whole blood, while the expression remained above baseline for CD4+ 
cells (26%, n=30, P<0.001) and reticulocytes (42%, n=30, P<0.001).  Whole blood 
and reticulocytes demonstrated a transient 42% and 56% downregulation (n=30, 
P<0.001) of IMPDH2 expression, while CD4+ cells displayed a transient elevation of 
15% (n=30, P=0.009). The predose activity in CD4+ cells (after removal of MPA) 
demonstrated a transient 90% increase (P<0.001) the first day after transplantation, 
which coincided with the upregulation of IMPDH 1 and 2 expression. In contrast, the 
corresponding predose activity of IMPDH in whole blood decreased the first couple 
of days posttransplant. This correlated with the regulation of IMPDH2 in reticulocytes 
(Figure 15).  
 
The initial regulation of the IMPDH genes was observed in both patients with and 
without MMF and coincided with the administration of high-dose corticosteroids 
perioperatively. Further support of a relation to corticosteroids was provided by the 
appearance of similar gene expression changes in relation to corticosteroid based anti-
rejection therapy. Corticosteroids demonstrate concentration-dependent effects and 
influence multiple signal transduction and gene expression pathways. This includes 
suppressing inflammatory genes, activating several anti-inflammatory genes and 
increasing the degradation of messenger RNA encoding inflammatory proteins.19 
Still, gene expression effects provoked by the transplantation cannot be excluded. 
MPA did not appear to have a profound effect on IMPDH expression the first days 
after transplantation, although this cannot be ruled out since all patients were on a 
high glucocorticoid dosage during this period.  
 
Potential induction of IMPDH expression 
During the second week posttransplant, the patients with and without MMF displayed 
separate trends of IMPDH expression. Reticulocytes from the patients on MMF 
therapy demonstrated a gradual increase of both isoforms starting around one week 
posttransplant (Figure 15). Individual MMF patients showed IMPDH 1 and 2 
increases reaching 8.7 and 2.4 times above baseline expression at the last observation 
day. When comparing the treatment groups, MMF treated patients demonstrated 
2.9-fold higher (P<0.05) IMPDH2 expression than the patients without MMF at the 
last observation day. Although not statistically significant, also IMPDH1 expression 
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tended to be higher among MMF patients. Similar, but less pronounced upregulation 
was observed in whole blood. The increase in IMPDH 1 and 2 expressions was 
accompanied by a gradual increase in whole blood activity. These trends might result 
from enzyme induction under prolonged MMF treatment as discussed in Section 
1.4.4. However, effects of basiliximab in the non-MMF patients cannot be excluded 
and the magnitude of a possible induction is uncertain due to the simultaneous 
influence of considerable corticosteroid dosage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Potential induction of IMPDH 1 and 2 expression in reticulocytes. 
Median expression of IMPDH 1 and 2 (normalized to day 0) in reticulocytes from patients with 
(n=25) and without (n=5) mycophenolate mofetil (MMF) treatment. * significant (P<0.05) 
difference from pretransplant. ¤ significant (P<0.05) difference between groups. 
0.8
1.2
1.6
2.0
-2 0 2 4 6 8 10 12 14 16
0.0
0.4
0.8
1.2
-2 0 2 4 6 8 10 12 14 16
Days after transplantation
R
e
la
tiv
e
 
ge
n
e
 
e
xp
re
ss
io
n
IMPDH2
M
et
hy
lp
re
d.
58
0 
+
 
80
 
m
g 
iv
M
et
hy
lp
re
d.
58
0 
+
 
80
 
m
g 
iv
IMPDH1
*
*
*
*
*
¤
Prednisolone: 80–20 mg 
MMF
Without MMF
Results and Discussion 
 69 
The whole blood samples reflect the total IMPDH expression and activity exhibited 
by the various blood cell populations. Erythrocytes, which constitute the largest blood 
cell population, probably dominate the IMPDH activity measured in whole blood. The 
clinical relevance of an induction in reticulocytes is not known and whole blood 
measurements might not reflect the activity in the cells of interest.  
 
Acute rejection 
A comparison of patients with (n=11) and without (n=19) acute rejection episodes 
during the follow-up, revealed higher (P=0.017) pretransplant IMPDH2 expression in 
CD4+ cells from the patients with rejection. Despite the significant influence of 
immunosuppressive therapy on gene expression posttransplant, the IMPDH2 
expression among the patients with rejection seemed to be higher throughout the 
observation period (Figure 16). This correlation between IMPDH2 expression and the 
occurrence of rejection is in agreement with the correlations between high IMPDH 
activity pretransplant and at day 6 posttransplant and the risk of rejection as discussed 
in Section 1.4.4.209,210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Higher IMPDH2 expression in CD4+ cells from patients with 
rejection. 
Median IMPDH2 expression in CD4+ cells in patients with (n=11) and without (n=19) acute 
rejection. Vertical bars represent the range of observed expressions. * Significant (P<0.05) 
difference between groups. 
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The mechanisms of immune activation and graft rejection include expression and 
coregulation of multiple genes. High IMPDH2 expression may be a surrogate marker 
for increased activation of lymphocytes, which again could be caused by a higher 
level of T cell presensitization.194 The trend (ns, P=0.142) towards higher rejection 
rates in the population receiving dialysis pretransplant with 50% rejection episodes 
compared to 21% among patients without dialysis could also be explained by 
presensitization. Previous investigations have demonstrated higher risk of rejection in 
renal transplant patients receiving dialysis prior to transplantation compared to 
patients without dialysis.236,237 The initial elevation of IMPDH activity in CD4+ cells 
coincided with increased expression of IMPDH 1 and 2 in the same cells. This might 
be a response to immune activation and inflammation related to the transplantation, as 
well as the suggested impact of corticosteroids.  The relation between IMPDH and 
immune activation is also addressed in Section 1.4.3. 
 
The correlation between IMPDH2 expression and acute rejection episodes supports 
the potential of MPA individualization based on IMPDH measurements in 
lymphocytes. Indeed, additional studies are required to characterize the association 
between IMPDH, immune activation and occurrence of acute rejections. Furthermore, 
the influence of cellular presensitization suggests that monitoring of effector/memory 
T cells as discussed in Section 1.4.2, may be a promising approach to support rational 
therapeutic decisions. 
 
4.3 Paper III 
A majority of studies concerning IMPDH regulation have been performed ex vivo in 
isolated cells or in immortalized cell lines. However, such studies may not reflect the 
in vivo conditions and gene regulation mechanisms. Furthermore, samples from MPA 
treated patients often involve comedication, e.g. corticosteroids, CNI and T cell 
depleting therapy, as well as lymphocyte populations of variable activation status. 
This could influence the IMPDH expressions and complicate the interpretation of 
specific MPA effects. We investigated the effects of MPA on IMPDH 1 and 2 
expression in CD4+ cells and whole blood from healthy individuals receiving MMF 
doses of 100−1000 mg.  
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Regulation of gene expression in response to MPA exposure 
The predose expression of IMPDH2 was generally higher than IMPDH1 in both 
CD4+ cells (3.6-fold) and whole blood (1.9-fold). The predose gene expressions 
displayed 2−3 fold variability between individuals, being highest for IMPDH1 
expression in CD4+ cells.  Furthermore, 12-hour intervals without MPA exposure 
demonstrated relatively stable expression of both IMPDH isoforms. Following intake 
of MMF, expression of IMPDH1 decreased rapidly in CD4+ cells, as well as in whole 
blood. In CD4+ cells, MMF doses of 250 and 500 mg caused median 29% (P=0.043) 
and 39% (P=0.043) suppression of IMPDH1 expression, respectively. The expression 
of IMPDH2 was less influenced by MPA. Still, a significant downregulation of 
IMPDH2 (10%, P=0.043) was observed in CD4+ cells following intake of 500 mg 
MMF. MMF doses of 1000 mg were associated with smaller, non-significant 
reductions of IMPDH 1 and 2 expression. The initial reduction was mostly followed 
by increasing expression, which exceeded baseline expression within some of the 
intervals. This upregulation was most pronounced in whole blood where increments 
up to 2.4-fold and 75% above baseline were observed for IMPDH 1 and 2 expression, 
respectively, 24 hours after MMF doses of 1000 mg. The interindividual PK 
variability of MMF was substantial and the effects of MPA exposure were thus 
studied in terms of MPA plasma concentrations (Cmin, Cmax and AUC0−12h). The gene 
expression responses appeared to be strongest correlated with MPA AUC0−12h. We 
demonstrated a biphasic IMPDH1 expression response to MPA exposure not 
previously described. At MPA AUC0−12h below 20 mg×h/L, increasing MPA exposure 
was associated with larger reductions of IMPDH1 expression in whole blood 
(r=−0.82, P<0.001) and CD4+ cells (r=−0.50, P<0.057). At MPA AUC0−12h exposure 
exceeding 20 mg×h/L, the influence on IMPDH1 gene expression shifted and higher 
MPA exposure was correlated with smaller reductions of IMPDH1 in both CD4+ 
cells and whole blood (r=0.42, ns, and r=0.77, P<0.05). Inverse correlations between 
MPA concentration and time to minimum gene expression, further support an MPA 
exposure-dependent regulation of the IMPDH genes. The timescale for the changes 
suggests that the expression in whole blood is largely influenced by nucleated cells.  
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Gene expression in relation to enzyme activity and purine nucleotides 
The enzyme activity of IMPDH showed a strong and immediate inhibition by MPA. 
In addition to this expected direct inhibition of MPA on IMPDH activity, reduced 
expression of IMPDH 1 and 2 might contribute to the total reduction of enzyme 
activity. The maximum inhibition of IMPDH activity occurred at MPA AUC0−12h of 
22 mg×h/L, approximately coinciding with the maximum reduction of IMPDH1 
expression. No further reductions in enzyme activity were observed with MPA 
exposure exceeding this level, while the reductions of IMPDH1 expression were 
smaller with higher MPA concentrations.207 It could be hypothesized that these 
smaller reductions of gene expression might contribute to the plateau effect of 
IMPDH inhibition.  
 
In contrast to an expected decrease, we observed elevated guanine nucleotide levels in 
CD4+ cells after MMF intake. The participants were exposed to single doses of 
MMF, and this limited duration of MPA exposure might not yield sufficient IMPDH 
inhibition for effective intracellular depletion of guanine nucleotides. Furthermore, 
activation of salvage enzymes in response to reduced de novo guanine synthesis, or by 
increased substrate availability,226 could explain the elevations of purine nucleotides 
that were observed postdose in this study. Similar responses of ATP, not being a 
product of IMPDH, and GTP, support the hypothesis that alternative enzymatic 
pathways are involved. However, further studies, including multiple dosing, are 
necessary to characterize the mechanisms leading to purine nucleotide fluctuations. 
 
The biphasic expression response to MPA could be explained by negative feedback 
regulation of IMPDH1 expression by guanine nucleotides. At MPA AUC0−12h below 
20 mg×h/L, increasing MPA exposure was associated with elevated guanine 
nucleotides as well as larger reductions of IMPDH1 expression. At MPA exposure 
exceeding this threshold, the influence on IMPDH1 expression shifted and higher 
MPA exposure was correlated with smaller reductions of IMPDH1, as well as a trend 
towards larger increases of expression 8−24 hours postdose. This was accompanied 
with decreased purine nucleotide pools in three of the individuals, reaching 47% of 
baseline GTP AUC0−12h. Indeed, the guanine nucleotide response at high MPA 
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exposure was variable207 and not closely associated with either MPA exposure or gene 
expression response. This may be attributed to variable degrees of compensating 
mechanisms like induction of the HPRT and IMPDH enzymes. An alternative 
explanation might be that the biphasic response is mediated through two distinct 
mechanisms.  
 
Expression of the IMPDH genes during MPA exposure could also be regulated 
through other mechanisms than guanine nucleotide levels. The presence of MPA or 
the inhibition of IMPDH activity might directly influence the gene expression. 
Recently, the in vivo generated MPA metabolite, AcMPAG, has been reported to 
regulate gene expression of IL-2 and nucleobindin 1, independent of guanine 
nucleotide levels.238 
 
Further studies are needed to confirm the concentration-dependent effects of MPA on 
IMPDH 1 and 2 expressions and to identify the mechanism of this regulation. The 
single-dose design did not allow investigation of steady state MPA concentrations. 
Indeed, the MPA concentrations obtained at the high single doses were comparable to 
clinically relevant exposure. Future studies should rather address possible long-term 
alterations of guanine or deoxyguanine nucleotides and the potential relationship to 
clinical efficacy of MPA. Furthermore, since the majority of lymphocytes from 
healthy individuals are resting cells, studies in activated lymphocytes would probably 
be relevant for estimation of immunosuppressive effects.  
 
4.4 Paper IV 
This is the first study of MPA PK and PD among renal allograft recipients receiving 
belatacept compared to patients with CsA. All patients received allografts from 
deceased donors and pretransplant dose interval investigations were thus not feasible.  
 
Pharmacokinetics 
Early posttransplant, belatacept patients showed higher MPA concentrations, as well 
as more pronounced secondary concentration peaks, than CsA patients. Despite MMF 
dose reductions for two belatacept patients, the MPA exposure increased significantly 
(P=0.031, n=6) from week 2 to week 13 when considering the whole population. The 
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elevation was especially pronounced among the CsA patients and might be related to 
the tapering of CsA and corticosteroid doses and improvement of renal function. 
These findings are in agreement with the previously reported increasing MPA levels 
after transplantation and the interaction between CsA and MPA (Section 1.3.2).  
 
Pharmacodynamics 
There was no tendency towards induction of predose IMPDH activity or expression  
in CD4+ cells with time since transplantation. However, the IMPDH response within 
dose intervals changed with time. Early posttransplant, there was an inverse 
correlation between MPA exposure and IMPDH activity. At week 13, IMPDH 
activity increased postdose within both treatment groups, reaching up to 7 times 
predose activities before returning towards predose levels. Considering the IMPDH 
AUC0−9h activity, up to 3.6-fold higher activity was observed at week 13 compared to 
week 1. The MPA PK and PD profiles of a representative belatacept treated patient 
are given in Figure 17.  
 
With respect to the IMPDH 1 and 2 gene expression in CD4+ cells, rapid and 
transient changes were observed for IMPDH1 while the expression of IMPDH2 was 
relatively stable. Increasing MPA exposure was associated with larger inductions of 
IMPDH1 expression (AUC0−9h: r=0.81, P=0.027, n=7). The maximum IMPDH1 
expression was 52 (13−177)% higher 13 weeks posttransplant compared to week 1 
(P=0.031, n=6). This might contribute to the associated elevation of IMPDH activity 
at week 13. The pretransplant expression of IMPDH2 was 2.1 (1.6–2.7) times higher 
than IMPDH1 in CD4+ cells. A relative increase of IMPDH1 versus IMPDH2 
expression supports marked contributions of IMPDH1 to the measured activity within 
dosing intervals. 
 
The present changes of IMPDH activity and IMPDH1 expression in CD4+ cells are 
consistent with previous observations in PBMCs from transplant patients as discussed 
in Section 1.4.4.212 The expression of IMPDH1 may be regulated by feedback 
mechanisms through changes in guanine nucleotide pools as suggested in Paper III.  
Concomitant measurement of guanine nucleotides and gene expression in a larger 
cohort is necessary to confirm this hypothesis. 
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Figure 17. PK-PD profiles of mycophenolic acid (MPA).  
Representative MPA pharmacokinetic (PK) and pharmacodynamic (PD) profiles at 2 and 13 
weeks posttransplant in a patient receiving mycophenolate mofetil in combination with 
belatacept. A: IMPDH activity (% of predose) in CD4+ cells and MPA plasma concentration 
versus time (hours) postdose. B:  Gene expression of IMPDH1 (% of predose) in CD4+ cells 
versus time postdose.  
 
We investigated a population of relatively old patients (median age; 71 years), 
receiving quadruple immunosuppressive regimens including induction therapy 
(basiliximab). The patients demonstrated relatively low predose IMPDH activity. 
According to the hypothesis presented in Section 1.4.4, the induction of IMPDH 
activity and IMPDH1 expression within dose intervals might be an MPA response 
that is primarily observed in resting lymphocytes with low basal IMPDH activity. 
However, the clinical relevance of the altered PD response to MPA remains to be 
elucidated. Even if the present regulation does not influence MPA efficacy, the 
findings should be considered when interpreting IMPDH measurements. Our data 
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suggest that assessment of basal IMPDH levels (pretransplant or predose after 
transplantation) might be a more feasible strategy for MPA monitoring than 
determination of relative changes after dose.  
4.5 Limitations 
The major limitation of the clinical studies (Papers II-IV) is the relatively low number 
of investigated individuals. This implies that the results should be interpreted with 
caution and that future prospective studies with larger cohorts are required to confirm 
the findings. Furthermore, the small groups in the study presented in Paper IV did not 
provide sufficient power to detect potential differences between the treatment groups.  
Moreover, heterogeneous patient populations with respect to immunosuppression and 
presensitization complicated the interpretation of the observations. The two weeks 
follow-up in the study presented in Paper II was based on a pilot study, but appeared 
to be relatively short for assessment of a potential IMPDH induction in erythrocytes. 
Moreover, potential effects of comedications like basiliximab, exogenous 
erythropoietin or the antiviral prophylaxis cannot be excluded. End stage renal 
disease, dialysis and the transplant surgery are other conditions possibly influencing 
gene expression. Since all patients received high-dose corticosteroids and underwent 
transplantation, we were not able to control for effects related to these parameters 
(Paper II and IV). Potential effects of the surgery could have been assessed by 
concomitant investigations in the donor population.  
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5. Conclusions of the Thesis 
 
We developed and validated an assay for measurement of IMPDH1 and IMPDH2 
gene expression in blood cells. The assay was further utilized for analysis in clinical 
samples from transplanted patients and healthy individuals.  
 
A descriptive study in 30 renal allograft recipients suggested substantial impact of 
corticosteroids, and potentially also the surgery, on the expression of IMPDH1 and 
IMPDH2. The regulation differed between isoforms and cell types. Furthermore, an 
induction of both isoforms in reticulocytes could be related to MPA. We also 
observed a significant association between pretransplant expression of IMPDH2 in 
CD4+ cells and the risk of rejection.  
 
The exposure-response study in five healthy individuals demonstrated that 
administration of clinically relevant MMF doses was associated with significant 
expression changes of IMPDH1, which traditionally is regarded as the constitutive 
isoform. Only smaller alterations were observed for IMPDH2 expression. The 
regulation of IMPDH1 seemed to depend on MPA exposure, and could be mediated 
through alterations in guanine nucleotide pools.  
 
Investigations of MPA PK-PD in belatacept versus CsA patients revealed significant 
changes of MPA PD with time since transplantation. Although no trend of induction 
was observed with respect to IMPDH predose activity in CD4+ cells, significant 
increases of enzyme activity were observed within the dose intervals at week 13 
compared to week 1. This was observed both in cyclosporine and belatacept treated 
patients, and despite higher MPA exposure. This could be explained by a concomitant 
increase of IMPDH1 expression, possibly mediated by reduced guanine nucleotide 
levels. Furthermore, the MPA exposure seemed to be lower early posttransplant 
among the CsA patients, which could be expected on the basis of the reported CsA 
induced reductions in MPA exposure. No pronounced effects were observed of 
belatacept per se on MPA PK or PD.  
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The validated real-time RT-PCR assay, and the use of a reference gene index for 
normalization, ensured reliable quantification of IMPDH 1 and 2 expression. 
Altogether, our data support the potential of PD monitoring based on IMPDH levels 
in lymphocytes. However, the significant impact of corticosteroids and MPA should 
be considered when interpreting IMPDH measurements. We observed complex 
regulation of IMPDH 1 and 2 gene expression and distinct mechanisms are probably 
involved during immune activation and in response to MPA exposure. Indeed, the 
detailed mechanisms of the gene expression changes remain to be elucidated.  
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6. Future Perspectives 
 
Optimization of MPA therapy might increase the therapeutic potential of the drug in 
transplantation as well as within other fields of immune modulation. The best way to 
individualize MPA therapy has still not been defined, and monitoring of PD 
parameters like IMPDH activity is investigated as a complimentary tool to PK 
monitoring. Measurement of gene expression, as an alternative to enzyme activity, 
allows sensitive assessment of the two isoforms separately. Indeed, establishment of a 
feasible PD monitoring strategy requires further characterization of the relation 
between the potential IMPDH parameters and clinical outcome. Standardization of 
assays is required to allow comparisons between studies. 
 
The selection of optimal PD markers and sampling strategy should be based on 
clinical studies in relevant populations. An ongoing descriptive study at 
Rikshospitalet University Hospital investigates the MPA PK-PD relationship in liver 
transplant patients to define eligible IMPDH parameters and a feasible sampling 
strategy for PD monitoring in these patients. Finally, the usefulness of IMPDH based 
PD monitoring strategies needs to be evaluated in randomized, controlled, prospective 
trials.  
 
We and others have revealed significant alterations of the IMPDH response with 
prolonged MPA treatment. In PBMCs and CD4+ cells, a potential feedback regulation 
of the enzyme was observed, which attenuated the inhibitory action of MPA. 
However, the findings are conflicting and clinical evidence does not suggest reduced 
efficiency of MPA with time. It could be speculated that the variable IMPDH 
response between studies might be related to the proportion of proliferating versus 
non-proliferating lymphocytes in the analyzed samples. This hypothesis should be 
addressed in further studies. Moreover, the variable IMPDH responses within dose 
intervals suggest that the basal or predose activity of IMPDH might be a better 
parameter for PD monitoring than the relative IMPDH inhibition. Indeed, this needs 
further elucidation.  
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Other potential tools for individualization of MPA therapy might be assessment of 
non-specific biomarkers of immune status and pharmacogenetic measurements.  
 
The IMPDH isoenzymes play a critical role in cell proliferation and differentiation 
and are considered important drug targets for anticancer, antiviral and 
immunosuppressive treatment. Characterization of the regulation and involvement of 
the specific isoenzymes in immunological and malignant proliferation might 
contribute to the processes of drug development and establishment of strategies for 
monitoring effect and disease activity. The gene expression assay we have developed 
is a useful tool for such applications. 
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Abstract 
The objective of this study was to investigate the pharmacokinetics (PK) and 
pharmacodynamics (PD) of mycophenolate (MPA) in combination with belatacept (2nd 
generation CTLA4-Ig) or cyclosporine (CsA). Seven renal allograft recipients were 
randomized to either belatacept (n=4) or cyclosporine (n=3) based immunosuppression. 
Samples for MPA PK and PD evaluations were collected predose and at 1, 2 and 13 weeks 
posttransplant. Plasma concentrations of MPA were determined by HPLC-UV. Activity of 
inosine monophosphate dehydrogenase (IMPDH) and the expressions of two IMPDH 
isoforms were measured in CD4+ cells by HPLC-UV and real-time reverse-transcription 
PCR, respectively. Subsets of T cells were characterized by flow cytometry. The MPA 
exposure tended to be higher among belatacept patients than in CsA patients at week 1 
(P=0.057). Further, MPA concentrations (AUC0−9h and C0) increased with time in both groups 
and were higher at week 13 than at week 2 (P=0.031, n=6). In contrast to the postdose 
reductions of IMPDH activity observed early posttransplant, IMPDH activity within both 
treatment groups was elevated throughout the dosing interval at week 13. Transient postdose 
increments were also observed for IMPDH1 expression, starting at week 1. Higher MPA 
exposure was associated with larger elevations of IMPDH1 (r=0.81, P=0.023, n=7 for MPA 
and IMPDH1 AUC0−9h at week 1). The maximum IMPDH1 expression was 52 (13−177)% 
higher at week 13 compared to week 1 (P=0.031, n=6). One patient showed lower MPA 
exposure with time and did neither display elevations of IMPDH activity nor IMPDH1 
expression. No difference was observed in T cell subsets between treatment groups. The 
significant influence of MPA on IMPDH1 expression, possibly mediated through reduced 
guanine nucleotide levels, could explain the elevations of IMPDH activity within dosing 
intervals at week 13. The present regulation of IMPDH in CD4+ cells should be considered 
when interpreting measurements of IMPDH inhibition.  
 3 
Introduction 
The increasing understanding of T cell activation mechanisms reveals new promising targets 
for immunomodulation. Belatacept is a second generation cytotoxic T-lymphocyte antigen-4 
(CTLA4)-Ig fusion protein that via high affinity binding to CD80 and CD86 provides T cell 
anergy and apoptosis.1 
 
The current immunosuppressive regimens in transplantation are mainly based on calcineurin 
inhibitors (CNI), which have lead to dramatic improvements in short-term outcome after 
transplantation. However, long-term use is associated with nephrotoxicity and cardiovascular 
morbidity that may lead to increased risk of late allograft loss and death. Belatacept is 
investigated as an alternative to CNI following transplantation. A phase 2 trial in renal 
allograft recipients (n=218) reports similar efficacy, higher glomerular filtration rates and less 
frequent chronic allograft nephropathy with belatacept compared to cyclosporine (CsA).2  
 
Mycophenolic acid (MPA) is widely used in combination with CNI, corticosteroids, and 
frequently also induction therapy to prevent rejections posttransplant. Currently, two MPA 
formulations are available, the prodrug ester mycophenolate mofetil (MMF) and the enteric-
coated mycophenolate sodium.  
 
Inosine monophosphate dehydrogenase (IMPDH) catalyzes the rate-limiting step of de novo 
guanine nucleotide synthesis. The enzyme activity is constituted by two isoenzymes, encoded 
by IMPDH1 and IMPDH2, which have similar kinetic properties and share 84 % identity at 
the amino acid level.3 However, the regulation and expression of the isoenzymes differ, and 
gene knockout models indicate distinct functions of IMPDH 1 and 2.4,5 Lymphocyte 
activation is associated with elevation of both isoenzymes, while neoplastic cells display 
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marked up-regulation of IMPDH2.6,7 MPA exerts its immunosuppressive action by inhibiting 
IMPDH, and thereby the proliferation of activated lymphocytes.8 
 
Despite substantial pharmacokinetic (PK) and pharmacodynamic (PD) variability of MPA, 
most protocols prescribe fixed doses ranging from 0.75 to 1.5 g MMF twice a day. Several 
strategies have been suggested to individualize MPA therapy and improve the clinical 
outcome after transplantation. The area under the MPA concentration versus time curve 
(AUC) from 0 to 12 hours correlates with clinical outcome after transplantation9 but is 
impractical for routine monitoring, and various limited sampling schemes are evaluated.10,11  
 
Measurement of IMPDH activity may provide a more direct estimation of drug efficacy, and 
is investigated as a PD approach for individualization of MPA therapy.12,13 Long-term MPA 
treatment has been associated with induced IMPDH activity and expression.14-18 However, the 
results are conflicting and depend on the investigated cell populations and methodology. 
Furthermore, concomitant medications (e.g. high doses of corticosteroids) and the 
transplantation surgery itself may influence the activity and expression of IMPDH.17 The 
clinical implications of these findings remain to be elucidated. 
 
To date, only limited data are available concerning PK and PD of MPA in combination with 
belatacept. The present study is a supplemental study appended to the BENEFIT-EXT phase 3 
trial in transplant patients receiving grafts from extended criteria donors (BMS protocol 
IM103027).19 This is an observational, pilot study in renal transplant patients receiving MMF 
in combination with either belatacept or CsA. The objective was to investigate PD and PK 
characteristics of MPA in the two treatment groups. Measurements of MPA concentrations 
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were used for PK evaluations, while PD investigations involved determination of IMPDH 
activity, analyses of IMPDH 1 and 2 expression and characterization of T cell subpopulations.  
 6 
Materials and methods 
Study objects  
From October 2006 to February 2007, seven adult patients receiving grafts from extended 
criteria donors were included in the BENEFIT-EXT study at Rikshospitalet University 
Hospital. Extended criteria donors were defined as donor age above 60 years, donor age above 
50 years and other donor co-morbidities, cold ischemia time above 24 hours or donation after 
cardiac death. The inclusion and exclusion criteria are described in detail in the BENEFIT-
EXT study protocol.19 Patients were randomized into three arms with CsA in one arm and 
belatacept (less intensive or more intensive, respectively) in the two others. Belatacept was 
administered as a 30 min intravenous (iv) infusion at intervals as described.19 Additional 
immunosuppression consisted of MMF (CellCept®, Roche, Basel, Switzerland) 1 g twice 
daily, corticosteroids and induction therapy with basiliximab (Simulect®, Novartis, Basel, 
Switzerland) 20 mg on day 0 (transplantation day) and day 4. Corticosteroids were given as iv 
methylprednisolone on day 0 and 1, followed by per oral prednisolone starting at 80 mg/day, 
tapered by 10 mg/day to 20 mg/day, maintained at 15 mg/day the second month and at 10 
mg/day the third month. CsA was dosed according to protocol to reach target whole blood 
through concentrations (C0) of 150−300 µg/L the first month posttransplant, and then lowered 
to 100−250 µg/L.  
 
The protocol of both the BENEFIT-EXT trial and the present sub-study were approved by the 
regional committee for medical research ethics. The BENEFIT-EXT protocol was also 
approved by the Norwegian Medicines Agency. Written informed consent was obtained from 
all participants. 
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Samples 
Samples were collected at one occasion before transplantation and for 9 hour-profiles at 
approximately 1, 2 and 13 weeks posttransplant (referred to as week 1, 2 and 13). Samples for 
9 hour-profiles were drawn after an overnight fast before administration of the morning dose 
of immunosuppression, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6 and 9 hours post-dose. IMPDH 
expressions were not determined at 0.5 and 1.5 h. Cell subsets were only characterized 
predose and 2 h post-dose. At each time point 10 ml whole blood was collected in EDTA 
tubes. Samples were immediately processed for CD4+ cell isolation, separation of plasma and 
staining of cells for flow cytometric characterization.  
 
Enzyme activity and gene expression measurements were performed in CD4+ cells, which are 
relevant considering their role in allograft rejection as well as being a target for the action of 
MPA. The cells were isolated from whole blood within an hour after sampling by using 
paramagnetic beads with antibodies against CD4 (Dynabeads® CD4, Invitrogen, Carlsbad, 
CA) as described in detail elsewhere.20,21  
 
To evaluate the variability of IMPDH activity and gene expression without influence of 
medication or exposure to alloantigens, CD4+ cells from healthy individuals (n=5) were 
investigated. Samples were drawn every 2 hours over 6 hour intervals starting at 8 AM as 
described in detail elsewhere.13,22  
 
Concentrations of immunosuppressive drugs 
Total plasma concentrations of MPA were measured by high-performance liquid 
chromatography assay with UV-detection (HPLC-UV).23 Routine measurement of whole 
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blood CsA C0 was performed by the CEDIA® immunoassay (Microgenics corp., Fremont, 
CA) on a Modular analytics instrument (Roche Diagnostics, Mannheim, Germany). 
 
Enzyme activity 
For the quantification of IMPDH activity in CD4+ cells, intracellular MPA concentrations 
were restored by incubating the isolated cells in filtrated plasma originating from the same 
sample. The IMPDH activity was determined in cell lysates using an HPLC-UV assay for 
determination of xanthine derived from xanthosine monophosphate (XMP).20 Activities were 
expressed as the XMP production rate (pmol XMP per 1.0 × 106 CD4+ cells per min). For 
each dosing interval, predose (A0), maximum (Amax) and minimum (Amin) enzyme activities 
were determined. Enzyme activity AUCs were calculated from 0−9 hours and 0−6 hours.  
 
Gene expression 
The gene expressions of IMPDH 1 and 2 in CD4+ cells were quantified by a validated reverse 
transcription-PCR method on a LightCycler® 480 instrument (Roche Applied Science) as 
previously described.21 Briefly, total RNA was extracted and reverse transcribed using 
random primers. Sequences of IMPDH1 and IMPDH2, and the reference genes 
aminolevulinate delta-synthase1, β2-microglobulin and ribosomal protein L13A, were 
amplified in separate reactions including hybridization probes for specific real-time product 
detection. Crossing points were defined by the second derivative maximum method and target 
gene expressions were calculated relative to the geometric mean expression of the reference 
genes. As for IMPDH activity, predose (E0), maximum (Emax) and minimum (Emin) gene 
expression and AUCs were calculated for each profile.  
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Quantification of T-cell subsets  
The numbers of total T cells (CD3+), as well as subpopulations of helper (CD4+) and 
cytotoxic (CD8+) T cells were determined by flow cytometry. These subsets were further 
characterized based on the expression of CD45RA and CD45RO isoforms indicating naïve 
and antigen experienced (activated/memory) lymphocytes, respectively. 
 
Absolute quantification of T-cell subsets was performed using TruCount tubes according to 
the manufacturer’s instructions. Briefly, 50 µL EDTA blood was added to tubes containing a 
given number of beads and cells were stained with titrated amounts of anti-CD3-PerCP, anti-
CD45 RO-PE, anti-CD45 RA-APC and anti-CD4-FITC or anti-CD8-FITC monoclonal 
antibodies (mAb). Isotype-matched control anti-mouse mAb and non-labeled cells were 
included for each sample. Erythrocytes were lysed by adding 450 µL FACS Lysing Solution. 
The tubes and all reagents were supplied by BD (Becton Dickinson Biosciences, Oxford, 
UK). Flow cytometric analyses were performed within 24 h after labeling on a FACSCalibur 
(BD) flow cytometer using the CellQuest Software (BD) for data acquisition. The bead 
population and CD3+ cell versus side scatter population were manually gated.  
 
Data analysis and statistics  
Results of the RT-PCR assays were analyzed using the LightCycler 480 Software v.1.5 
(Roche Applied Science). All gene expression measurements were performed in triplicate. 
Absolute cell counts were calculated by the CellQuest Software based on the gated bead 
population.  
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Post-dose data of gene expression and enzyme activity were normalized to individual predose 
levels. AUCs were calculated by the linear trapezoid method. All results are presented as 
median (range) unless otherwise specified.  
 
Statistical tests were performed using SPSS statistical software version 16.0 (SPSS Inc., 
Chicago, IL). The Mann-Whitney test was used for comparisons of unpaired data, while the 
Wilcoxon signed rank test was used for paired data. Pearson's r was used for correlation 
analyses. Statistical significance was considered at P<0.05 (two-tailed). 
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Results 
Patient population 
The planned enrolment for the BENEFIT-EXT trial at Rikshospitalet University Hospital was 
12 patients. However, only 7 patients receiving allografts from extended criteria donors were 
recruited at our center within the inclusion period. Out of these, 3 patients were randomized to 
receive CsA, while 4 patients received belatacept regimens.  
 
Demographic and clinical data were collected from medical records and baseline 
characteristics are summarized in Table 1. There were no significant demographic differences 
between the treatment groups. One of the belatacept patients withdrew from the study after 
the 6 h post-dose sampling at week 2. Data from this profile were omitted from the AUC 
calculations.  
 
All patients received prophylactic antiviral therapy consisting of valganciclovir or 
valaciclovir. No cytomegalovirus breakthrough disease was identified during follow-up. 
Biopsies were performed in cases of suspected rejection (Banff ´97 grading system).24 No 
cases of biopsy verified acute rejection, graft loss or death were observed within the 13 weeks 
follow-up. Plasma concentrations of albumin, total bilirubin, and ALAT were stable 
throughout the study period. 
 
MPA pharmacokinetics  
Two patients, both in the belatacept arm, had their MMF dosing reduced to 1.5 g/day between 
weeks 2 and 13, both due to drops in leukocyte count. The other patients remained on MMF 
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doses of 1 g twice a day throughout the follow-up. Pharmacokinetic data of MPA are 
summarized in Table 2 and concentration profiles are depicted in Figure 1. The 
interindividual variability in MPA concentration was substantial and highest early 
posttransplant. Within the whole group, up to 4- and 7-fold differences were observed for 
MPA C0 (week 2) and AUC0-9h (week 1), respectively. The first week posttransplant, MPA C0 
seemed to be higher among belatacept patients (P=0.057, n=4 and n=3) and 3 of 4 belatacept 
patients demonstrated higher MPA AUC0-9h than the CsA patients. 
 
The maximum plasma concentrations (Cmax) of MPA appeared 1 (0.5−2) hour postdose. 
Following Cmax, secondary MPA concentration peaks were observed 5 (2−9) hours postdose 
and were more pronounced for belatacept patients than for CsA patients. Limited MPA 
concentration profiles were calculated from 4 to 9 hours to estimate potential impact of 
enterohepatic circulation. The MPA AUC4-9h was numerically higher among belatacept 
patients than for CsA patients at week 1, being 15.2 (10.4–27.1) mg x h/L and 7.8 (6.2–13.3) 
mg x h/L, respectively (P=0.114, n=4 and n=3).  
 
Doses of CsA were tapered according to CsA C0 measurements and were median 550 
(450−825) mg, 550 (400−575) mg and 300 (300−350) mg at week 1, 2 and 13, respectively. 
The corresponding CsA C0 were median 190 (160–380) µg/L, 265 (180−295) µg/L and 175 
(140−180) µg/L. The reduction of CsA exposure was accompanied by increasing MPA 
concentrations. The association between MPA C0 and CsA C0, as well as CsA dose, displayed 
correlation coefficients (r) of −0.74 (P=0.023, n=9; pooled CsA data) and −0.79 (P=0.012, 
n=9), respectively. 
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Considering the entire study population, the lowest MPA exposure was observed at week 2 
and then increased with time. At week 13, MPA C0 was 60 (26−200)% higher (P=0.031, 
n=6), while MPA AUC0−9h was 43 (11−67)% higher (P=0.031, n=6) compared to week 2. The 
elevation seemed to be most pronounced in CsA patients, although no significant difference 
was detected between groups (Table 2).  
 
At week 1, MPA exposure was inversely correlated to bodyweight, with correlation 
coefficients of −0.90 (P=0.005, n=7) and −0.80 (P=0.031, n=7) for MPA C0 and AUC0-9h, 
respectively. However, no significant relations were detected at later observations. Adjusted 
for bodyweight normalized doses, patients with belatacept displayed numerically higher MPA 
C0 than CsA patients, being 0.22 (0.18−0.23) mg/L per mg/kg and 0.13 (0.07−0.17) mg/L per 
mg/kg at week 1 (P=0.057, n=4 and n=3). The MPA exposure did not seem to be associated 
with plasma albumin, ALAT or bilirubin. 
 
Enzyme activity 
Summarized data of IMPDH activity are presented in Figure 1 and Table 2. Pretransplant 
activity was variable and tended to be higher among CsA patients compared to belatacept 
patients. Following transplantation, predose activities (A0) seemed to be influenced by the 
present MPA C0, and no consistent trends were observed for A0 versus time since 
transplantation (Table 2). 
 
The postdose activities of IMPDH were strongly influenced by MPA exposure. At week 1, the 
activity profiles for 6 of the patients were inversely related to MPA concentrations with 
maximum 57 (42–75)% enzyme inhibition around MPA Cmax (Figure 1). The AUC0−9h 
activity displayed inverse correlations to MPA C0 (r=–0.91, P=0.012, n=6) and MPA Cmax 
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(r=–0.86, P=0.028, n=6), implying greater inhibition of IMPDH with higher MPA exposure. 
However, this relation changed with time posttransplant. At week 13, IMPDH activity 
increased postdose within both treatment groups, reaching up to 7-times A0 before returning 
towards predose activities (Figure 1). Considering AUC0−9h activity, 4 of 6 patients 
demonstrated substantial increases reaching 3.6 times the activity of week 1 (Figure 3). 
Compared to week 2, the AUC0−9h activity was 81 (25–322)% higher at week 13 (P=0.063, 
n=5). Higher MPA Cmax was associated with increasing IMPDH activity, expressed as 
AUC0−9h (r=0.80, P=0.058, n=6) and Amax (r=0.88, P=0.051, n=6). Compared to healthy 
controls (n=5), the CsA treated patients (n=3) showed higher IMPDH AUC0−6h activity at 
week 13 (P=0.036). Within the belatacept group, 2 of 3 patients displayed higher activity than 
the controls.  
 
Gene expression 
The pretransplant expression of IMPDH2 was 2.1 (1.6–2.7) times higher than IMPDH1 in 
CD4+ cells. Predose expressions (E0) of IMPDH 1 and 2 were highest and most variable the 
first week posttransplant, being 104 (20–150) % and 18.8 (7.2–75) % above the levels at week 
13, respectively (P=0.031, n=6 for both). Predose expressions were comparable at week 2 and 
13 (Table 3).  
 
The 9 h profiles showed rapid changes of IMPDH1 expression postdose, while IMPDH2 
expression was relatively stable (Figure 2). At week 1, IMPDH1 expression was transiently 
upregulated for belatacept patients, while CsA patients displayed downregulation. With 
longer time on immunosuppressive therapy, including higher MPA exposure, increasing 
transient inductions of IMPDH1 expression were observed postdose for both treatment groups 
(Table 3). At week 13, the maximum expression (Emax, % of E0) of IMPDH1 was 52 
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(13−177)% higher than at week 1 (n=6, P=0.031). A similar trend was observed for IMPDH1 
AUC0−9h expression (n=6, P=0.094). Compared to healthy controls (n=5), the patients (n=6) 
demonstrated higher IMDPH1 Emax at week 13 (P=0.004), being 101 (100−116)% and 167 
(118–193)%, respectively. Considering IMPDH1 AUC0−6h expression, CsA patients (n=3) 
displayed higher levels at week 13 than controls (P=0.036). Among belatacept patients (n=3), 
IMPDH1 AUC0-6h expression was elevated at week 1 (P=0.032) and tended to be increased at 
week 13 (P=0.071), compared to healthy controls. One of the patients with MMF dose 
reduction experienced lower MPA exposure with time, and did neither display elevations of 
IMPDH activity nor IMPDH1 expression (Figure 3). The first week posttransplant, IMPDH1 
AUC0−9h expression correlated with MPA C0 (r=0.76, P=0.047, n=7) and MPA AUC0−9h 
(r=0.81, P=0.027, n=7). An association was also observed between minimum IMPDH1 
expression (Emin) and MPA AUC0−9h (r=0.82, P=0.023, n=7). This implies that higher MPA 
exposure is associated with larger increases of IMPDH1 expression post-dose. 
 
The IMPDH1 isoform demonstrated stronger correlations to IMPDH activity than IMPDH2. 
At week 1, there was an inverse correlation of –0.88 (P=0.02, n=6) between IMPDH1 Emax 
and IMPDH Amax indicating that lower IMPDH activity was accompanied by larger elevations 
of IMPDH1 expression. This relation changed with time, and 13 weeks posttransplant 
IMPDH1 AUC0–9h expression displayed positive correlations with IMPDH AUC0−9h activity 
(r=0.94, P=0.005, n=6) and Amax (r=0.90, P=0.038, n=5). Although IMPDH2 was the 
dominant isoform predose, the ratio of IMPDH2 to IMPDH1 expression declined after dosing 
toward ratios of about 1 for some patients.  
 
No significant associations were observed between activity or gene expressions of IMPDH 
and age, time since transplantation, dialysis, infections or HLA-DR mismatches. 
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T-cell subsets 
Characterization of T-cell subsets was only performed in 6 of the 7 patients, for technical 
reasons. 
 
Before transplantation, patients demonstrated a wide range of T cell counts, with up to 2.2- 
and 2.8-fold variation for both CD4+ and CD8+ cells. Following transplantation, the number 
of both subpopulations tended to decrease among belatacept patients while the T cell profiles 
for CsA patients were more variable. At week 2, two of three CsA patients displayed up to 2-
fold increases of CD4+ and CD8+ T cells, while reductions of 16.5 (7.7−49.5)% and 31.7 
(32.0−49.6)% were observed for belatacept patients.   
 
The proportions of naïve (CD45RA) and memory (CD45RO) T cells were comparable in both 
treatment groups, displaying CD45RA to CD45RO ratios of 0.61 (0.37−1.0) and 1.7 (1.1−3.0) 
for CD4+ and CD8+ cells (n=6), respectively, before transplantation. The percentage of 
CD4+ cells with memory phenotype tended to decline posttransplant within both groups. At 
week 13, the proportion of memory CD4+ cells was 12.3 (3.5−22)% (P=0.063, n=6) lower 
than pretransplant.  
 
The largest alteration in T-cell subsets from pre- to post-dose, was observed for CD4+ cells at 
week 13 with reductions of 45.8 (24.6–52.8)% (n=6, P=0.063). However, the proportions of 
naïve and memory cells were comparable before and after dose.  
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Discussion 
This is the first study of MPA PK and PD among renal allograft recipients receiving 
belatacept compared to patients with CsA. Data from healthy individuals were included to 
account for possible diurnal or random variability of IMPDH.  
 
Although standard MMF doses were applied, there was a considerable variability of MPA 
exposure among individuals. Early posttransplant, belatacept patients showed higher MPA 
concentrations, as well as more pronounced secondary concentration peaks, than CsA 
patients. Other comedication and parameters of renal and hepatic function were similar 
between the groups, and the inverse correlation between CsA and MPA concentrations 
suggest an effect of CsA on MPA exposure. Despite MMF dose reductions for two belatacept 
patients, the MPA exposure increased significantly from week 2 to week 13 when considering 
the whole population. The elevation was especially pronounced among the CsA patients and 
might be related to the tapering of CsA and corticosteroid doses and improvement of renal 
function.  
 
The PK of MPA is reported to be influenced by renal function, albumin levels and 
concomitant medications.25 Genetic polymorphisms of transporters, e.g. multidrug resistance-
associated protein 2 (MRP2), and UDP-glucuronosyltransferases may also contribute to 
variable MPA exposure.26,27 Several studies have reported lower MPA concentrations when 
used in combination with CsA than used with tacrolimus, sirolimus or alone.28,29 This is 
probably due to CsA mediated inhibition of MRP2, which is involved in enterohepatic 
circulation of MPA.30 Furthermore, MPA exposure is reported to increase with time 
posttransplant. The mechanisms are multifactorial and may include changes in comedication, 
protein binding, renal function, liver disease and red blood cell counts.31,32 
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In contrast to the inverse relation between MPA concentrations and IMPDH activity in CD4+ 
cells early posttransplant, prolonged MPA administration was associated with transient 
elevations of activity within dose intervals. This shifting IMPDH response is supported by the 
opposite correlations at week 1 and 13 between MPA exposure and IMPDH activity, and may 
provide an explanation for why higher concentrations of MPA do not result in markedly 
higher inhibition.13 
 
The regulation of the two IMPDH isoenzymes was further investigated by gene expression 
analysis. Following dosing, the expression of IMPDH1 displayed rapid and transient changes. 
Increasing MPA exposure was associated with larger inductions of IMPDH1. This might 
contribute to the associated elevation of IMPDH activity at week 13. The relative increase of 
IMPDH1 versus IMPDH2 expression supports marked contributions of IMPDH1 to the 
measured activity within dosing intervals. 
 
The present changes of IMPDH activity and IMPDH1 expression in CD4+ cells are consistent 
with previous observations in mononuclear cells from transplant patients.18 In addition, a 
study in healthy volunteers receiving different doses of MMF reported that regulation of 
IMPDH1 expression was associated with MPA exposure.22 The IMPDH1 gene may be 
regulated through changes in guanine nucleotides, or potentially by direct effects of MPA. 
Previous reports suggest negative feedback regulation of IMPDH by guanine nucleotides in 
cultured human cells and in yeast.{Glesne, 1991 825 /id;Escobar-Henriques, 2001 7 /id} In 
CD4+ cells from healthy individuals, low MPA exposure seemed to be associated with 
elevations of guanine nucleotides and subsequent reductions of IMPDH1 expression.13,22 In 
contrast, higher and repeated MPA exposure may lead to depletion of intracellular guanine 
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nucleotides and subsequent upregulation of IMPDH1 expression as was observed in the 
present study. Concomitant measurement of guanine nucleotides and gene expression in a 
larger cohort is necessary to confirm this hypothesis. Furthermore, potential effects of 
comedications like corticosteroids, basiliximab or the antiviral prophylaxis cannot be 
excluded. 
 
Prolonged MPA administration has been associated with increased predose IMPDH activity 
in whole blood and erythrocytes but not lymphocytes.14-17 The rapid and transient induction of 
IMPDH in CD4+ cells contrasts the gradual elevation in erythrocytes, which may originate 
from an induction in earlier differentiation stages that persists during erythrocyte maturation.  
 
Traditionally, IMPDH1 has been regarded constitutive, while IMPDH2 was considered to be 
the inducible isoenzyme and primary target for immunosuppression.35 More recent findings 
reveal that both isoenzymes are essential for lymphocyte proliferation and potentially 
important for immunosuppressive effects.6 Furthermore, associations between genetic variants 
of IMPDH1 and a form of autosomal dominant retinitis pigmentosa have increased the 
interest in this isoform.36 The current study emphasizes different genetic control of the 
isoenzymes in CD4+ cells. Although the detailed mechanisms are unknown, IMPDH1 is 
reported to be subject to complex regulation involving three promoters and various 
transcripts.37 Because IMPDH2 is approximately 5 times more sensitive to MPA than 
IMPDH1,38 a relative increase of IMPDH1 could have implications for the MPA effect.  
 
Previous studies have described reduced CD4+ cell counts after initiation of 
immunosuppression.39 This was also observed for the belatacept patients in the present study. 
In contrast, the increased CD4+ cell counts for two CsA patients at week 2 may be attributed 
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to immune activation. Furthermore, the tendency towards reduced proportions of CD4+ 
memory cells within both treatment groups at week 13 may be explained by the current 
immunosuppression. It has generally been accepted that memory T cells do not require CD28-
CD80/CD86 costimulation for recall responses. Recent studies have suggested that T cell 
costimulation is required for optimal IL-2 production and proliferation of both naïve and 
memory CD4+ T cells.40 Despite having different mechanisms of action, both belatacept and 
CsA interfere with the IL-2 pathway, supporting the similar effects on T cell subsets. 
However, several exogenous (e.g. other immunosuppressants) and endogenous factors (e.g. 
circadian rhythm, stress) may also influence lymphocyte subsets and should be accounted for 
in further studies. 
 
The isolation of variable numbers of CD4+ cells in each sample was compensated by relating 
IMPDH activity to cell counts and gene expressions to a reference gene index. However, 
various subsets of peripheral CD4+ T-cell may display different levels of IMPDH activity and 
gene expressions. Alterations in these subsets could thereby influence the measured activity 
and gene expression. Although CD4+ cell counts changed, the proportions of naïve and 
memory cells remained stable after dose, indicating that IMPDH changes are not an effect of 
altered CD4+ cell populations. 
 
The potential of a PD approach for MPA individualization has been supported by correlations 
between IMPDH levels and posttransplant outcomes. Sanquer et al. reported an up-regulation 
of predose IMPDH1 expression in mononuclear cells at acute rejection episodes.18 Moreover, 
high pretransplant IMPDH activity in mononuclear cells and IMPDH2 expression in CD4+ 
cells have been associated with acute rejection episodes.12,17 Recently, polymorphisms within 
the IMPDH1 and IMPDH2 genes have been suggested to impact baseline IMPDH activity 
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and outcomes after transplantation.41,42 Indeed, further investigations of IMPDH activity and 
regulation of the two isoenzymes are essential to elucidate the level of IMPDH inhibition that 
yields adequate immunosuppression. The present study suggests that MPA has a significant 
influence on IMPDH1 expression within the dose interval. This is an important aspect to 
consider when interpreting measurements of IMPDH inhibition. 
 
The major limitation of this study is the low number of enrolled patients. This implies that the 
results should be interpreted with caution and that future prospective studies with larger 
cohorts are required to confirm the findings. The clinical outcome, including renal function, is 
investigated in detail in the ongoing BENEFIT-EXT trial.19  
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Conclusion 
In the present study, the IMPDH activity in CD4+ cells throughout dose intervals was 
significantly increased by week 13 compared to early posttransplant. This was observed both 
in cyclosporine and belatacept treated patients, and irrespective of higher MPA exposure. A 
marked increase of IMPDH1 expression within dose intervals, possibly mediated by reduced 
guanine nucleotide levels, may explain this paradox. The differences in MPA exposure 
between CsA and belatacept treated patients were as anticipated with reference to the 
documented CsA induced reductions in MPA exposure. No pronounced effects were observed 
of belatacept per se on MPA PK or PD.  
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Figure legends 
Figure 1 
Median inosine monophosphate dehydrogenase (IMPDH) activity (% of predose) and 
mycophenolic acid (MPA) concentrations among renal allograft recipients. The vertical lines 
represent the range of total observations. Profiles of patients in the belatacept group (n=3) at 
weeks 1, 2 and 13 (A, B and C) and the cyclosporine group (n=3) at weeks 1, 2 and 13 (D, E 
and F). (Observe scale on right y-axis of C.) 
 
Figure 2 
Median gene expressions of IMPDH1 and IMPDH2 (% of predose) among renal allograft 
recipients. The vertical lines correspond to the range of total observations. Profiles of patients 
in the belatacept group (n=3) at weeks 1, 2 and 13 (A, B and C) and the cyclosporine group 
(n=3) at weeks 1, 2 and 13 (D, E and F). 
 
Figure 3 
Individual 0−9 h area under the curve (AUC) for 6 renal transplant patients at week 13 
compared to week 1. Solid lines denotes belatacept patients (n = 3) while broken lines 
represent CsA patients (n = 3). Data are provided for A: mycophenolic acid (MPA) AUC0−9h, 
B: inosine monophosphate dehydrogenase (IMPDH) activity AUC0−9h and C: IMPDH1 
expression AUC0−9h.  
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Tables 
 
Table 1. Patient characteristics 
 Belatacept (n=4) CsA (n=3) 
Age, years 74 (68 - 78) 66 (29 - 71) 
Gender, M/F 3/1  3/0  
Bodyweight, kg 63.1 (58.7 - 85.6) 92.3 (75.7 - 96) 
Body mass index, kg/m2 22.9 (18.6 - 28.0) 26.7 (23.1 - 26.9) 
Donor, DD/LD 4/0  3/0  
Previous transplants 0  0  
Dialysis pretransplant 3  1  
Observation day after transplantation 
(day 0)     
Week 1 7 (6 - 8) 6 (6 - 7) 
Week 2 14.5 (13 - 15) 16 (14 - 20) 
Week 13 90.5 (78 - 95) 91 (77 - 93) 
Number of HLA mismatches     
Total 2.5 (2 -3) 1 (0 - 3) 
DR 0.5 (0 - 1) 1 (0 - 1) 
Duration of cold ischemia (h) 16.5 (9.2 - 23.6) 13.4 (12.7 - 15.1) 
CMV serostatus     
D+/R+ 4  1  
D+/R- 0  2  
 
 
CMV, cytomegalovirus; D, donor; DD, deceased donor; LD, living donor; R, recipient 
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Table 2. MPA exposure and IMPDH activity 
   Treatment group Total 
MPA plasma 
concentration 
 Week Belatacept (n=4) Cyclosporine (n=3)  
1 3.1 (2.7-3.8) 1.4 (0.7-2.3) 2.7 (0.7-3.8) 
2 1.9 (1.7-5.5) 1.9 (0.8-2.3) 1.9 (0.8-5.5) C0 (mg/L) 
 
13 3.2 (2.9-7.6) 2.9 (2.4-3.0) 3.0 (2.4-7.6) 
1 44.4 (28.2-70.8) 37.1 (17.9-40.1) 40.1 (17.9-70.8) 
2 35.1 (33.6-47.6) 26.4 (16.3-37.8) 34.4 (16.3-47.6) AUC0-9h  (mg×h/L) 
 
13 48.5 (39.1-64.1) 37.4 (27.2-59.0) 43.8 (27.2-64.1) 
1 12.8 (7.7-15.4) 11.0 (5.2-19.5) 11.3 (5.2-19.5) 
2 12.1 (9.7-15.1) 7.8 (4.4-10.9) 10.9 (4.4-15.1) Cmax (mg/L) 
 
13 17.9 (8.1-21.4) 11.3 (5.3-13.7) 12.5 (5.3-21.4) 
         
IMPDH activity 
in CD4+ cells 
 
       
0 0.24 (0.16-0.31) 0.61 (0.3-0.95) 0.31 (0.16-0.95) 
1 0.96 (0.70-1.4) 0.63 (0.37-1.53) 0.92 (0.37-1.53) 
2 0.43 (0.25-0.71) 1.1 (0.66-1.53) 0.60 (0.25-1.53) 
A0 
(pmol/106 
cells/min) 
 
13 0.70 (0.32-2.7) 0.28 (0.2-1.87) 0.51 (0.2-2.72) 
1 760 (472-908) 1197 (904-1491) 884 (472-1491) 
2 1168 (694-3142) 760 (488-1032) 1032 (488-3142) AUC0-9h (% of A0×h) 
 
13 3034 (414-3784) 3044 (765-3111) 3039 (414-3784) 
1 45.5 (25.4-58.1) 46.1 (39.0-100) 46.1 (25.4-100) 
2 77.4 (48.0-100) 64.3 (32.6-96.0) 77.4 (32.6-100) Amin (% of A0) 
 
13 100 (7.6-100) 100 (13.0-100) 100 (7.6-100) 
1 141 (103-184) 170 (100-254) 160 (100-254) 
2 255 (113-524) 119 (100-137) 184 (100-524) Amax (% of A0) 
 
13 627 (106-707) 523 (148-525) 524 (106-707) 
 
 
Data are given as median (range). The belatacept group includes 3 patients at week 13 and for 
the maximum, minimum and AUC calculations at week 2. A0, predose activity; Amax, 
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maximum activity; Amin, minimum activity; AUC, area under the variable versus time curve; 
C0, predose concentration, Cmax, maximum concentration; Cmin, minimum concentration, 
IMPDH, inosine monophosphate dehydrogenase; MPA, mycophenolic acid. 
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Table 3. IMPDH 1 expression 
 
Table 3. IMPDH1 expression 
   Treatment group Total 
IMPDH1  Week Belatacept (n=4) Cyclosporine (n=3)  
0 0.63 (0.54-0.76) 0.44 (0.37-0.79) 0.59 (0.37-0.79) 
1 0.56 (0.32-1.1) 0.75 (0.67-0.75) 0.67 (0.32-1.1) 
2 0.45 (0.17-0.54) 0.54 (0.43-0.62) 0.50 (0.17-0.62) 
E0 
 
 
13 0.42 (0.25-0.59) 0.31 (0.30-0.43) 0.36 (0.25-0.59) 
1 1018 (866-1128) 794 (736-881) 880 (736-1128) 
2 1146 (781-1278) 784 (741-1146) 1145 (741-1622) 
AUC0-9h  
(% of E0×h) 
 
 
13 1070 (911-1201) 1291 (1193-1540) 1197 (911-1540) 
1 85.3 (75.3-115) 69.3 (46.8-92.2) 82.0 (46.8-115) 
2 94.4 (80.2-103) 71.1 (60.7-94.3) 87.3 (60.7-103) Emin  (% of E0) 
 
13 97.0 (57.2-99.6) 113 (89.5-117) 98.3 (57.2-117) 
1 140 (108-143) 105 (102-122) 121 (102-143) 
2 147 (105-189) 107 (104-151) 127 (104-189) Emax (% of E0) 
 
 
13 161 (133-196) 203 (173-222) 185 (133-222) 
 
 
Data are given as median (range). The belatacept group includes 3 patients at week 13 and for 
the maximum, minimum and AUC calculations at week 2. E0, predose expression; Emax, 
maximum expression; Emin, minimum expression; AUC, area under the variable versus time 
curve.  
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